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Abstract 
The levels of cAMP are regulated by phosphodiesterases (PDE), which are targets for 
the treatment of inflammatory disorders. The overarching goal of this study was to 
harness recent successful developments in PDE research for the treatment of 
experimental autoimmune encephalomyelitis (EAE) and ultimately human autoimmune 
diseases. We report here that PDE8A exerts its control of T cell function through the 
Raf-1 kinase signaling pathway. The highly PDE8-selective enzymatic inhibitor PF-
04957325 significantly suppresses rolling and adhesion of in vivo MOG35-55 activated 
inflammatory CD4+ T effector (Teff) cells while interacting with inflamed brain 
endothelial cells under shear flow conditions. Recently, PDE8A was shown to associate 
with Raf-1 creating a compartment of low cAMP around Raf-1 thereby protecting it from 
protein kinase A (PKA) mediated inhibitory phosphorylation. Disruption of the PDE8A-
Raf-1 complex by disruptor peptide (DP) significantly reduces adhesion of Teff cells to 
endothelial cells. We further observed that disrupting PDE8A-Raf-1 through DP 
specifically reduces adhesion, spreading and locomotion of Teff cells while interacting 
with the vascular adhesion molecule ICAM-1. Our investigation of the effect of PDE8 
inhibitor on chronic and relapsing-remitting (EAE) in vivo indicates suppression of  
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clinical and histopathological signs of disease. PDE8 inhibitor affects accumulation of 
CD4+ T cells into the spinal cord. In addition, there is a reduction in pro-inflammatory  
cytokines TNF-α and IL-17 production in the spinal cord after PDE8 inhibition in vivo. 
Collectively, our studies demonstrate that PDE8A inhibition by enzymatic inhibitors or 
PDE8A-Raf-1 kinase signaling complex disruptors significantly decreases Teff cell 
adhesion and migration on endothelial cells, and represents a novel approach to treat 
autoimmune inflammation in vivo.  
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Chapter 1 
Introduction 
1.1 Steps in leukocyte migration into inflamed tissue 
Circulating blood leukocytes need to migrate through activated venular walls into the 
lymphoid organs or the peripheral sites of infection, injury and stress in order to 
eliminate the inflammatory trigger and contribute to tissue repair. Original leukocyte 
cascade had three steps: rolling, chemokine triggered integrin activation and integrin 
dependent arrest. Recently added evidence in integrin activation, post-adhesion events 
and transendothelial migration has led to an expanded version of the original three step 
cascade. The updated cascade has the following events: rolling, adhesion 
strengthening, intraluminal crawling, paracellular/ transcellular migration and migration 
through the venule basement membrane (1).  
A. Leukocyte rolling 
The first step in leukocyte migration cascade is weak, transient adhesive interactions of 
circulating leukocytes with endothelial cells in the venule walls. This step is mediated by 
P select glycoprotein ligand 1 (PSGL-1) expressed on leukocytes and P- and E- 
selectins expressed on endothelial cells. L and P selectins require shear stress in order 
to support rolling and adhesion. Rolling cells detach when flow is stopped. Selectins 
have the catch bond characteristics, which make molecular bonds stronger when pulling 
force is applied. Shear stress (dyn/cm2) is defined as the force (dyn) exerted by flowing 
blood on each unit area of endothelial surface (cm2). This initial rolling interaction is 
stabilized by leukocyte microvilli flattening, long tethers at rear end and structures 
known as slings (2). α4β1 integrin and α4β7 integrin also mediate rolling while 
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interacting with vascular adhesion molecule 1 (VCAM-1) and mucosal vascular 
addressin cell adhesion molecule 1 (MADCAM-1) respectively. LFA-1 (lymphocyte 
function antigen 1) in intermediate affinity conformation also can support rolling step. E-
selectin, LFA-1 integrin and MAC-1 (αMβ2) integrin mediate slow rolling in which cells 
roll in venules at a velocity of under 5 µm per second.  
B. Leukocyte activation and arrest 
Rolling stabilization facilitates engagement of leukocyte chemokine receptors and 
integrins with endothelial cell chemokines and ligands respectively ultimately leading to 
leukocyte arrest (3). Shear flow applied to the migrating leukocytes can increase 
leukocyte –endothelial cell contact by deforming the leukocyte and facilitating their 
exposure to chemokines displayed on endothelial cell surface (4). Two major adhesion 
molecule families important for leukocyte adhesion are β1 and β2 integrins.  Leukocyte 
arrest on inflamed venules requires activation of one of the major integrins- LFA-1 
(expressed on all effector leukocytes), VLA-4 (expressed on monocytes, eosinophils, 
effector T cells and B cells), MAC-1 (expressed on neutrophils and monocytes). 
Integrins can also be activated via outside - in signaling, independent of chemokines 
(5). Chemokines rapidly regulate integrin avidity by increasing both integrin affinity and 
valency of ligand binding. Chemoattractants trigger G protein couple receptor (GPCR) 
activation, which then stimulates inside out signaling leading to integrin activation on 
leukocytes by triggering complex intracellular signaling network within milliseconds (6). 
Integrin affinity corresponds to conformational changes in individual integrin 
heterodimer, which leads to decrease in rate of ligand dissociation. Inside out signaling 
induces transition of integrins from bent to intermediate to high affinity conformation 
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leading to opening of the ligand binding pocket. Valency corresponds to density of 
integrins per area of plama membrane involved in adhesion, which can be dependent 
on lateral mobility and cell surface expression level of integrins. 
C. Intraluminal crawling 
Post-arrest leukocytes can protrude and undergo trans-endothelial migration via 
paracellular endothelial cell junctions or crawl on the surface for exit cues. This crawling 
step is chemokine-GPCR mediated and integrin dependent process (7). Chemokine-
GPCR mediated signaling lead to Gi protein mediated activation of guanine nucleotide 
exchange factors (GEFs). This in turn triggers activation of Rho family GTPases and 
Rap-1 GTPases and their downstream effector molecules leading to conformational 
activation of integrins and microclustering of ligand occupied integrins at various ventral 
focal points. Actin cytoskeleton reorganization to generate a protrusive leading edge 
and contractile uropod at the rear end, integrin recycling at the leading edge, polarized 
fusion of vesicles containing signaling molecules are the events mediating leukocyte 
crawling. Leukocytes use numerous millipede- like integrin molecules to scan the 
activated endothelial surface. 
D. Trans-endothelial migration 
In order to cross the blood vessel, the leukocytes have to pass through three distinct 
barriers- endothelial cells, venule basement membrane and pericytes (5). Leukocyte 
migration through endothelial cell take < 2-5 minutes, but penetrating the basement 
membrane can take between > 5-15 minutes. Leukocytes can cross the endothelium 
either by passing through the junctions between adjacent endothelial cells (paracellular 
route) or by passing through the endothelial cells (transcellular route). The paracellular 
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TEM is the route used by 70-90% leukocytes while the transcellular route is a relatively 
low frequency event (8). However, brain vascular endothelial cells utilize the 
transcellular route due to the specialized tight junctions, which restricts the paracellular 
route. Shear flow though restricts the initial recruitment at vascular site, positively 
regulates leukocyte transendothelial migration (TEM) across endothelium (9).  
Integrin mediated leukocyte adhesion leads to multiple changes in the endothelial cells 
such as ICAM-1 clustering, concomitant VCAM-1 recruitment to membranous 
structures, which facilitates leukocyte adhesion and TEM. Binding of leukocytes to their 
vascular ligands ICAM-1, VCAM-1 triggers downstream signaling in endothelial cells. 
These events include increase in intracellular Ca+2, reactive oxygen species (ROS) 
generation, activation of p38 mitogen activated protein kinase (MAPK) pathway, 
tyrosine phosphorylation of endothelial junction molecules. These events can occur 
along side activation of RhoA GTPase and its downstream effector molecule Rho 
activated protein kinase (ROCK), which control actin cytoskeletal machinery as well as 
endothelial myosin light chain kinase.  The breaching of the endothelial cells is 
regulated by major endothelial cell adhesion molecules: adherens junctions such as 
cadherins and tight junctions: junctional adhesion molecules (JAM), endothelial cell 
selective adhesion molecule (ESAM) and claudins. Vesiculo - vacuolar organelles 
(VVOs) - small membrane associated passageways, or channels formed by endothelial 
ligands can act as route for leukocyte passage via the transcellular route. Once 
leukocytes extravasate the endothelial cells, they still need to cross through the pericyte 
sheath and endothelial cells basement membrane (BM) in order to exit the venular wall. 
Pericytes are mural cells that form second layer of the venules, and are found in a 
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discontinuous manner wrapped around endothelial cells and embedded in venule BM. 
Pericytes express adhesion molecules, chemokines, receptors for pro-inflammatory 
molecules which aid in the leukocyte trafficking.  
Treatment with anti-α4 integrin antibody has been shown to treat EAE and prevent 
accumulation of leukocytes in the CNS in EAE (10, 11). Natalizumab – an antibody 
against the α4 subunit of VLA-4 reduced the development of brain lesions in MS 
patients and is now an approved therapy for treating patients with MS (12, 13). This 
suggests that drugs that inhibit migration of inflammatory leukocytes into the CNS can 
be effective in treating inflammatory disease. 
 
1.2   Role of cAMP and Phosphodiesterases (PDEs) in T cells 
cAMP signaling is known to inhibit T cell activation, proliferation and cytokine release 
(14-16). Activation of Gs protein coupled receptors via ligands such as prostaglandins, 
adenosine, catecholamines and histamines results in accumulation of intracellular 
cAMP and leads to suppression of immune responses in vitro and in vivo (17, 18). PDE 
are the only known enzymes that are able to hydrolyze and hence maintain spatial and 
temporal control over formation of cAMP gradients within a cell (19, 20). PDEs are 
divided into 11 different gene families based on their specificity for cAMP or cGMP, 
structural similarity and mode of regulation (21). Specific PDE forms induced in 
activated lymphocytes are PDE1, PDE3, PDE4, PDE7 and PDE8 (16, 22-25). Out of 
these, PDE3, PDE4B and to a lesser extent PDE7A are the major forms of PDE 
expressed in activated T cells (26). The PDE4 inhibitor - rolipram has been used to 
ameliorate clinical signs of experimental autoimmune encephalomyelitis (EAE) models 
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and reduce CNS inflammation when treatment is started after immunization or after 
onset of disease (27, 28). PDE3 inhibitors alone are ineffective at treating Th1 
mediated disorders. But PDE4 inhibitor and low doses of PDE3 inhibitors - cilostamide 
in combination synergistically inhibit T cell proliferation and pro-inflammatory cytokine 
production of human cells (26). PDE7 inhibitors have proved ineffective in suppressing 
T cell proliferation and mice deficient in PDE7A have functional T cells (29, 30). But 
PDE7 inhibitors when used in combination with PDE4 inhibitors show an additive effect 
(31). These reports suggest that probably there might be other PDEs expressed in T 
cells that might be important for controlling T cell function. Our previous work has 
shown that PDE8 is important for chemotaxis of T cells, adhesion of T cells to 
endothelial cells and breast cancer cell motility (24, 32, 33). PDE8 has a very high 
affinity for cAMP with a km value in the range of 40-150 nM (40 fold higher than that of 
PDE4) and hence might function at lower cAMP concentrations than PDE4 (34). 
PDE8A is insensitive to inhibition by the non-specific PDE inhibitor IBMX but is 
inhibited by the PDE inhibitor dipyridimole (DP) (IC50 in the range of 4- 9 µM) (21).  
The similarities in the sequence and structural properties of the catalytic domains of 
PDEs imply that family specific PDE inhibitors that target the human PDE forms are 
likely to have the same potency in the corresponding mouse PDE (35, 36). We were the 
first to report the novel PDE8 inhibitor PF-04957325 (24). The effect of PDE8 inhibitor 
on chronic inflammation models has not been tested to date. To date, none of the PDE 
inhibitors have been approved for MS treatment. Rolipram failed to treat MS patients 
and also had adverse effects such as emesis at therapeutically relevant doses (21, 37).  
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1.3   Phosphodiesterase 8 (PDE8) 
The more recently discovered PDE8 family, encoded by the PDE8A and PDE8B 
genes, is characterized by high affinity and specificity for cAMP. The human PDE8A 
gene is located on chromosome 15q25.3 and PDE8B is located on chromosome 
5q13.3. PDE8 has high affinity for cAMP (KM = 40-150 nM). This means that PDE8 is 
able to metabolize cAMP at basal conditions or in cellular compartments where low 
levels of cAMP need to be maintained. The human PDE8 lacks the nuclear localization 
sequence that is present in the mouse PDE8. Thus it may localized in the cytosol or to 
the membrane due to the presence of sites for myristoylation. Cloning and 
characterization of cAMP-specific PDE8A and B were first reported in 1998 (34, 38, 
39). Subsequently, Wang et al. cloned cDNAs representing five full-length human 
phosphodiesterase (PDE) 8A splice variants (PDE8A 1–5) from testis and T cells (40) 
(Table 1). Five variants have been identified for variants for PDE8B (PDE8B 1-5) (41) 
(Table 2). The PDE8A1 and PDE8A2 isoforms are most abundantly expressed in 
various tissues. Structurally, PDE8 is hydrophilic protein containing an N-terminal REC 
domain, a PAS domain, and a C-terminal catalytic domain (Fig. 1). The function of PAS 
(Per, Arnt and Sim) domain in PDE8 is currently unknown although its role in lower 
eukaryotic organisms has been identified. The PAS domain is important in protein-
protein interaction and small molecule ligand binding. Overexpressed recombinant 
PDE8A in HEK cells interacts with IκB protein via its PAS domain and this interaction 
increases the activity the PDE8A in vitro (42). PDE8A mutants with deleted PAS 
domains have 6-fold lower activity, which indicates a regulatory role for PAS domains 
in PDE8A. The REC (Receiver) domain are present exclusively in the human PDE8 
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gene among all the mammalian PDEs. REC domain are involved in signal transduction 
in the bacterial two component system. More studies are needed to explore the role of 
PAS and REC domains in PDE8 regulation. Under elevated cAMP conditions, PDE8A 
is phosphorylated by PKA on serine 359 and this enhances activity of the enzyme (43). 
cGMP- and cAMP dual substrate PDE3B and cAMP-specific PDE4A, 4B, 4D, 7A1, 7A3 
and 8A1 are PDE isoforms expressed in T cells (15, 23, 24, 44). Work from Beavo lab 
has shown that human PDE8A1 mRNA and protein levels is increased in CD3 and 
CD28 stimulation (23). Previous work from our lab has also shown that PDE8A 
expression in activated CD4+ T cells in vitro and in vivo (24).  
 
1.4   Compartmentalized signaling 
Distinct, non-overlapping intracellular cAMP signaling compartments within a cell 
comprise of scaffolding proteins, cAMP effector proteins and PDEs. Each of this 
signaling compartment controls different cAMP regulated functions and targeting PDEs 
within these unique signaling complexes rather than the targeting the specific PDE 
gene family will be much more potent and effective treatment option. One example of 
this is the FAK/RACK1/PDE5D5 direction- sensing complex in invasive cancer cells 
specifically localizes to nascent integrin adhesions and leading edge of polarizing cells 
(45). PDE8A has been shown to interact with Raf-1 kinase without the need for 
accessory proteins or lipids and protect it from PKA mediated inhibitory 
phosphorylation (46). Hence we will explore the role of this complex in CD4+ T cells. 
 
1.5   ERK (extracellular signal regulated kinase) signaling pathway  
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Extracellular signal regulated kinases (ERK) are a part of the mitogen- activated 
protein (MAP) kinases family. MAP kinases are activated in response to growth factors, 
integrins, G-protein coupled receptors as well as other receptor tyrosine kinases and 
thus involves sequential recruitment of the kinases Raf, MEK and ERK (47). The Raf 
family consists of three serine/threonine kinases: A-Raf, B-Raf and C-Raf/Raf-1. Raf is 
recruited to the membrane by the GTPase Ras and gets activated due to 
dephosphorylation and phosphorylation events by phosphatases and kinases 
respectively. Activated Raf further phosphorylates and activates MEK, which in turn 
phosphorylates and activates ERK. The activated ERK translocates to the nucleus and 
can phosphorylate a wide range of substrates with divergent functions. B-Raf has been 
demonstrated to regulate VLA-4 integrin mediated adhesion in human T cells under 
shear stress. The ERK MAPK pathway has been shown to be important in regulating 
adhesion, spreading and cell migration (48, 49). 
 
1.6   Cross talk between cAMP and ERK signaling pathways 
The protein kinase Raf was the first protein identified to be involved in the cross talk 
between the two signaling pathways (50). Raf-1 is inhibited by protein kinase A 
mediated phosphorylation at Serine 259 (51). However elevated cAMP levels can lead 
to B- Raf activation which in turn activates ERK. Studies indicate that B-Raf mediated 
activation of ERK occurs via the G protein Rap-1. Protein tyrosine phosphatases (PTP) 
are able to dephosphorylate and deactivate ERK and hence are another point of cross 
talk between cAMP and ERK pathways. PKA - mediated phosphorylation of ERK2 
docking site of PTP ablates the docking of PTP and thus attenuates the 
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dephosphorylation of ERK. cAMP phosphodiesterases also are regulated by ERK and 
PKA. PDE4 long forms possesses two regulatory modules called UCR1 (upstream 
conserved region 1) and UCR2 located between the N terminal region and catalytic 
unit. The PDE4 short forms possess only UCR2 whereas PDE4 super short forms 
consist of a truncated form of UCR2. The UCR1 region contains the PKA serine 
phosphorylation site. For example: PDE4B, 4C and 4D long forms can be inhibited 
approximately 80% by ERK mediated phosphorylation at specific motifs located in their 
catalytic region. This provides a feedback loop where the inhibition of PDE4 by ERK 
causes a rise in cAMP levels leading to activation of PKA, which then phosphorylates 
PDE4 to overcome the ERK - mediated inhibition. However, ERK mediated 
phosphorylation of PDE4 short isoforms leads to PDE4 activation, whereas ERK 
phosphorylation of PDE4 super short forms has minimal inhibitory effect due to the 
absence of PKA target sites.  
 
1.7   Exploring PDEs as treatment avenues in inflammatory diseases 
Early studies on characterization of PDEs in human lymphocytes had shown them to be 
excellent targets for producing anti-inflammatory effects with PDE4 the predominant 
form expressed (52). But bringing PDE4 inhibitors into the clinics faced decades of 
challenges, mostly due to emetic side effects. However, the approval and clinical use of 
PDE inhibitors for the treatment of major human inflammatory disorders has now finally 
made tremendous progress over the last 6 years with indications expanding at an 
almost yearly pace.  A potent and selective PDE4 inhibitor, roflumilast, was developed 
and became the first PDE4-selective inhibitor to be approved. It was approved for 
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treatment of chronic obstructive pulmonary disease, first in the European Union in 2010, 
where it is marketed under the name Daxas, and then by the US FDA in 2011, 
marketed under the name Daliresp (53, 54). Subsequently another oral PDE4 inhibitor, 
apremilast, developed by Celgene and marketed under the name Otezla, was approved 
by the US FDA in 2014 for the indications of psoriatic arthritis and plaque psoriasis (55-
63).  And in December 2016, another PDE4 inhibitor, crisaborole, developed by Anacor, 
since acquired by Pfizer, was approved as a topical treatment for atopic dermatitis (64-
70).  There is currently intense further interest and activity in the development of PDE4 
inhibitors both for treatment of inflammation as well as other indications.  Additionally, 
selective inhibitors of other PDE gene families are also seeing widespread use for 
various indications.  The PDE5 inhibitors, sildenafil (Viagra), vardenafil (Levitra), 
tadalafil (Cialis) and avanafil (Strenda) for the indications of erectile dysfunction, 
pulmonary hypertension and benign prostate hypertrophy, and the PDE3 inhibitors, 
cilostazol (Pletal) for intermittent claudication and milrinone (Primacor) for heart failure.  
Hence PDE inhibitors are proving to be of great clinical benefit. 
 
 
 
 
 
 
 
 
 	 	 	 	 	12	
1.8   Hypothesis and Aims of the project 
Our overarching goal is to harness recent successful developments in PDE research for 
the treatment of autoimmune disease. After decades of research characterized by 
little progress and disappointing initial clinical results, considerable 
breakthroughs in PDE inhibitor therapy have finally been achieved. Using small 
molecule inhibitors or signaling complex disruptors, the proposed studies will elucidate 
the role the PDE8 and PDE8A-Raf-1 kinase complex in controlling inflammation and 
regulating Teff cell functions. This should ultimately lead to the identification of 
previously unrecognized drugable targets and potential development of novel 
therapeutic approaches to treat multiple sclerosis (MS) and other inflammatory 
diseases. Our central hypothesis is that inhibition of PDE8 expressed in activated 
Teff cells is capable of suppressing migration of these pathogenic cells into the 
CNS, while maintaining Treg cell migration and function. Our goal is to further 
explore the potential of PDE8A as an anti-migratory therapy to treat T cell mediated 
diseases. This would have a very significant impact on the treatment of MS and will also 
define new treatment avenues for this disease. Additionally, we will test whether the 
known limitations of PDE4 inhibition can be overcome by combination treatment of 
targeting PDE8 and PDE4 through a combination of signaling disruptors and 
experimental and approved PDE family selective inhibitors as well as PDE inhibitors 
with dual specificity. Our work would take advantage of recent major successes of PDE 
targeted treatments in human inflammatory diseases and successful results of these 
studies would reinvigorate PDE research in MS and provide novel highly therapeutic 
treatments for this disease.  
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 Specific Aim 1: Evaluating the role of PDE8 and the PDE8A-Raf-1 signaling 
complex in regulating CD4+ T cell motility.  
In this aim we examined the role of PDE8 and PDE8A-Raf-1 complex in controlling T 
cell adhesion in a functional assay under physiological shear flow conditions using the 
flow chamber model.  
Sub Aim 1a] To study the effect of the PDE8 enzymatic inhibitors and PDE8A-Raf-
1 complex disruptor peptide on interaction of activated Teff cells and Treg cells 
with LPS - activated brain endothelial cells. 
In collaboration with Pfizer Inc. our lab was the first to report a potent and novel PDE8 
inhibitor PF-04957325, which is now widely used to study PDE8 function [10]. PF-
04957325 inhibits PDE8A with an IC50 of 0.0007 µM. This aim was studied using the 
flow chamber assay which simulates the physiologic shear flow conditions and enables 
us to monitor the interaction of activated T effector cells (Teff cells) with endothelial cells 
[14]. In order to distinguish between the effect of the inhibitors or complex disruptors on 
Teff cells versus Tregs cells, we utilized the Foxp3gfp.KI mice (71).  
Sub Aim 1b] To study the effect of inhibition of PDE8 activity or PDE8A-Raf-1 
complex disruption on interaction of integrins expressed on T cells with 
immobilized vascular ligands in vitro using the flow chamber assay  
We have investigated whether interaction of the VLA-4 or LFA-1 integrin with their 
vascular ligands- vascular cell adhesion molecule 1 (VCAM-1) and intercellular 
adhesion molecule (ICAM-1) respectively is primarily affected by inhibition of PDE8 
activity or the PDE8A-Raf-1 kinase complex disruptor. 
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Specific Aim 2: Studying the role of PDE8 and PDE8A-Raf-1 complex in regulating 
ERK/MAPK signaling in TCR stimulated CD4+ T cells. 
PDE8A has been reported to interact with Raf-1 and protect it from inhibitory 
phosphorylation by PKA at S259 in HEK cells and also regulate downstream ERK 
signaling (46). In this aim, we have tested whether PDE8 and PDE8-Raf-1 complex 
regulates ERK signaling using western blot technique. Chapter 3 addresses the 
answers to the Aims 1 and 2 using the flow chamber assay and western blotting 
respectively. 
Specific Aim 3: To determine the therapeutic potential of targeting PDE8 in 
treating autoimmune inflammation in vivo.  
After exploring the PDE8 mediated regulation of CD4+ T cell motility in vitro, we have 
further tested whether targeting PDE8 can suppress EAE clinically and reduce 
accumulation of inflammatory cells in the CNS. Further we also analyzed whether CD4+ 
T cells subtypes (Th1/Th17 cells), as well as TNF-α, IL-17, IFN-γ and IL-10 cytokine 
production is affected by inhibition of PDE8. Chapter 4 addresses the questions in Aim 
3 in the EAE model. 
Sub aim 3a] To test the effect of the PF-04957325 on treating chronic and 
relapsing remitting (RR) EAE. MS is a chronic inflammatory demyelinating disease of 
the central nervous system (CNS). The pathologic features of the disease are by white 
and grey matter lesions with myelin, oligodendrocyte and neuroaxonal loss (72). It is 
generally accepted that the disease is initiated by breakdown of the blood brain barrier 
and trafficking of T cells into CNS leading to attack on CNS tissue and formation of 
lesions (73, 74). These MS plaques are characterized by the presence of CD4+ T cells, 
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CD8+ T cells, B cells and macrophages (75). Experimental autoimmune 
encephalomyelitis (EAE) is the animal model of MS used to study the underlying 
inflammatory and autoimmune mechanism as well as for evaluation of 
pharmacotherapies (12). EAE can be induced by either active immunization with 
protein/peptide or by passive transfer of encephalitogenic T cells (76). CD4+ T helper 
type 1 cells (Th1 cells) and the IL-17 producing CD4+ T cells (Th17 cells) are important 
for disease initiation and inflammation in EAE (73). Classical EAE is characterized by 
ascending tail paralysis beginning at the tail followed by hind limb paralysis and fore 
limb paralysis. In this aim we explored the therapeutic effect of targeting PDE8 in vivo in 
mice once they show clinical signs of disease. 
Sub aim 3b] To test whether targeting PDE8 suppresses accumulation of immune 
cells and inflammation in the CNS. In order to test whether our hypothesis that 
PDE8A regulates CD4+ T cell adhesion holds true in vivo, we tested whether inhibition 
of PDE8 in T cell mediated disease leads to suppression of CD4+ T cells into the CNS in 
a T cell mediated autoimmune disease - EAE. Also since PDE8 is expressed at lower 
levels in Treg cells compared to Teff cells, hence the treatment might have a selective 
effect on Teff cells and not Treg cells migration into the CNS. We have done histological 
analysis of the brains and spinal cord of EAE mice as well as used flow cytometry 
approaches to evaluate infiltrates accumulating in the after treatment with the PDE8 
inhibitor PF-04957325. We have also used flow cytometry to evaluate effect of PDE8 
inhibition in Th17 cells, Th1 cells as well as the immunoregulatory IL-10 producing Treg 
cells. 
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Sub aim 3c] Assess the effect of the PF-04957325 on peripheral lymphoid organs. 
We have done similar flow cytometry analysis of the cervical lymph nodes, draining 
inguinal lymph nodes and spleen. 
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Figure 1.1 
 
Figure 1.1. Leukocyte recruitment under shear flow conditions in the flow 
chamber assay (9).  
Diagram depicts the various steps of T cells interaction with brain endothelial cells 
under physiological shear flow conditions in vitro in the flow chamber assay.  
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Figure 1.2 
 
Figure 1.2. Schematic representation of structures of human PDE8A1 and 
PDE8B1 cDNA (41). 
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Table 1.1 PDE8A splice variants (40) 
 
 
Table 1.2 PDE8B splice variants (41) 
 
PDE8 splice 
variant 
Amino acid 
residues 
Molecular weight 
(kDa) 
Exons lacking 
 
PDE8B1 885 99 Exon 8, missing part 
of PAS domain 
PDE8B2 838 93.7 Exons 8, missing 
part of PAS domain 
PDE8B3 788 88 Exons 8-10, lacks 
PAS domain 
PDE8B4 865 96.8 Exon 2 
PDE8B5 830 93 Exon 12, hence 
missing region 
between PAS 
domain and 
catalytic area. 
 
 
 
 
 
 
 
 
 
 
 
 
PDE8 splice 
variant 
Amino acid 
residues 
Molecular weight 
(kDa) 
Exons lacking 
 
PDE8A1 829 93.3 Exon 8 
PDE8A2 783 88.3 Exon 8-9, missing 
PAS domain 
PDE8A3 449 51.2 Exons -7-9, lacks 
PAS domain 
PDE8A4 582 66 Exons 7-8, lacks 
second half of PAS 
domain 
PDE8A5 582 66 Has all 23 exons, 
Insertion of 198 
nucleotides 
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Chapter 2 
Differential expression and function of PDE8 and PDE4 in effector T cells: 
Implications for PDE8 as a drug target in inflammation 
2.1 Summary 
Abolishing the inhibitory signal of intracellular cAMP is a prerequisite for effector T (Teff) 
cell function. The regulation of cAMP within leukocytes critically depends on its 
degradation by cyclic nucleotide phosphodiesterases (PDEs). We have previously 
shown that PDE8A, a PDE isoform with 40-100-fold greater affinity for cAMP than 
PDE4, is selectively expressed in Teff versus regulatory T (Treg) cells and controls 
CD4+ Teff cell adhesion and chemotaxis. Here, we determined PDE8A expression and 
function in CD4+ Teff cell populations in vivo. Using magnetic bead separation to purify 
leukocyte populations from the lung draining hilar lymph node (HLN) in a mouse model 
of ovalbumin-induced allergic airway disease (AAD), we found by Western immunoblot 
and quantitative (q)RT-PCR that PDE8A protein and gene expression are enhanced in 
the CD4+ T cell fraction over the course of the acute inflammatory disease and recede 
at the late tolerant non-inflammatory stage. To evaluate PDE8A as a potential drug 
target, we compared the selective and combined effects of the recently characterized 
highly potent PDE8-selective inhibitor PF-04957325 with the PDE4-selective inhibitor 
piclamilast (PICL). As previously shown, PF-04957325 suppresses T cell adhesion to 
endothelial cells. In contrast, we found that PICL alone increased firm T cell adhesion to 
endothelial cells by approximately 20% and significantly abrogated the inhibitory effect 
of PF-04957325 on T cell adhesion by over 50% when cells were co-exposed to PICL 
and PF-04957325. Despite its robust effect on T cell adhesion, PF-04957325 was over 
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two orders of magnitude less efficient than PICL in suppressing polyclonal Teff cell 
proliferation, and showed no effect on cytokine gene expression in these cells. More 
importantly, PDE8 inhibition did not suppress proliferation and cytokine production of 
myelin-antigen reactive proinflammatory Teff cells in vivo and in vitro. Thus, targeting 
PDE8 through PF-04957325 selectively regulates Teff cell interactions with endothelial 
cells without marked immunosuppression of proliferation, while PDE4 inhibition has 
partially opposing effects. Collectively, our data identify PF-04957325 as a novel 
function-specific tool for the suppression of Teff cell adhesion and indicate that PDE4 
and PDE8 play unique and non-redundant roles in the control of Teff cell functions. 
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2.2 Introduction 
The second messenger cyclic adenosine monophosphate (cAMP) regulates a broad 
range of biological functions, including the maintenance of immune tolerance (77). 
cAMP controls the immune response mainly through activation of cAMP-dependent 
protein kinase A (PKA) which suppresses activation and function of effector T (Teff) 
cells (16, 18, 20, 77, 78). Recently, we and others have also determined a role for 
exchange protein activated by cAMP (Epac) in this process (79, 80). Formation of site- 
and function-specific cAMP gradients and spatially distinct signals within cells critically 
depend on degradation by phosphodiesterases (PDEs), a family of enzymes that 
hydrolyze cAMP. As a consequence of selective expression and signaling complex 
formation of PDEs, cAMP signaling is compartmentalized in cells (19, 81-83). This 
allows specific PDE isoforms to control distinct cellular functions.  Altered expression 
and positioning of particular PDE isoforms may affect cell and tissue function and lead 
to pathology. While PDE enzymes are encoded by 21 different genes, 11 gene families 
(PDEs 1-11) are currently noted based on sequence similarities and biochemical 
properties and functions (21, 84-87). Several transcription initiation sites and alternative 
splicing contribute to the formation of over 100 different forms of PDEs (21, 84-87). 
Based on the unique roles of individual PDEs, selective PDE inhibition by drugs is 
considered an attractive approach to modulate cell and tissue function. Due to their 
importance in governing subcellular temporal distribution of cyclic nucleotides, and their 
accessibility to potent small molecule inhibitors, PDEs make excellent drug targets, 
including in diseases associated with chronic inflammation (88-91).  
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PDE4, PDE7 and PDE8 enzymes are cAMP-specific PDEs expressed in T cells (21). 
After many years of preclinical development, two novel PDE4 inhibitors have recently 
been approved for clinical use in chronic obstructive pulmonary disease (COPD) and 
psoriatic arthritis (56, 59, 92-94). These successes prompted the preclinical 
development of numerous novel PDE4 inhibitors being tested as potential therapies in a 
wide range of inflammatory disorders. Since PDEs have different expression and 
functional profiles in different cell and tissues, a major goal is to selectively inhibit 
additional PDE families that are expressed in T cells in the hope that distinct and 
targeted therapeutic activity can be achieved without the side effects associated with 
PDE4 inhibitors. Previous studies indicated that the high affinity isoforms PDE7A and 
PDE8A are required for full T cell activation (15, 23). The more recently discovered 
PDE8 family, encoded by the PDE8A and PDE8B genes, is characterized by high 
affinity and specificity for cAMP. As we and others have shown, PDE8A is important in 
immune processes such as T cell activation, effector T cell adhesion and chemotaxis 
(24, 32, 79) as well as breast cancer cell motility (33). Until recently, pharmacological 
approaches to studying PDE8 function have been hampered by the lack of suitable 
inhibitors. Selective inhibitors of PDE8 enzymes were not available and PDE8 is 
insensitive to the broad methylxanthine based PDE inhibitors such as 3-isobutyl-1-
methylxanthine (IBMX). The broad PDE inhibitor dipyridamole (DP) was the only 
compound known to inhibit PDE8 enzymes, and its inhibition of these enzymes was 
somewhat weak (IC50 = 4-40 µM) (21). In 2010, we were the first to report a potent and 
selective PDE8 inhibitor developed by Pfizer Inc., PF-04957325, that is now widely used 
to study PDE8 function in vitro and in vivo (24, 46, 95-97). Our work showed that 
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inhibition of PDE8 with PF-04957325 suppresses two major T cell integrins and firm 
attachment of effector CD4+ T (Teff) cells to endothelial cells (24). Further, treatment of 
mice with PF-04957325 in vivo ameliorates the signs of experimental encephalomyelitis 
without the side effects associated with PDE4 inhibitor treatment (Basole and Brocke, 
unpublished results). 
To further delineate the specific functions of PDE8 selective inhibition in T cells and to 
explore the therapeutic potential of targeting PDE8, we probed its function by direct 
comparison of PDE8 inhibition to a PDE4 selective inhibitor with comparable potency, 
and to analyze PDE8 expression in immune responses in vivo utilizing a bi-phasic 
murine model of ovalbumin (OVA)-induced allergic airways disease (AAD). 
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2.3 Results 
Selective expression of PDE8A in CD4+ versus CD4- T cells in inflammation in 
vivo 
We previously determined the expression of PDE8A in Teff and Treg cells in vitro and in 
vivo after challenge with antigen (24, 79). Of note, PDE8B expression has not been 
detected in T cell populations (32, 39, 53). To address the question of whether PDE8 is 
a potential target for the therapeutic use of selective inhibitors in a T cell mediated 
inflammatory disease, we analyzed PDE8 expression in lymph nodes of mice 
challenged with OVA-AAD (98). Research over the last three decades has provided 
evidence that T helper 2 (Th2) CD4+ T cells are a major contributor to the development 
of AAD in animals and asthma in humans. Using a biphasic ovalbumin (OVA)–induced 
murine model of AAD (98), in which resolution occurs with long-term continuous antigen 
challenge, we separated HLN cells draining the lung tissue at different time points after 
AAD induction by OVA aerosol exposure (day 3, 7 and 42) into CD4+ from CD4- 
fractions by magnetic bead technique and determined the expression of PDE8A in 
these cell populations by Western immunoblot. We found that expression of PDE8A 
protein was higher in CD4+ T cells as compared to the CD4- LNC population at day 7 
and 42 after AAD induction in HLN (Figure 2.1 A, B). This was not seen in ILN cell 
populations (Figure 2.1 C, D). Collectively, these data suggest that PDE8A protein 
abundance is higher in the HLN CD4+ T cell population than in the HLN CD4- cell 
population at the acute intermediate and later stage of AAD. In contrast, in both HLN 
and ILN, PDE8A protein expression was lower in CD4+ T cells as compared to the CD4- 
LNC population at the early acute stage of AAD on day 3 (Figure 2.1). Of note, this 
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selective expression pattern was not seen with PDE4B isoforms (data not shown). In 
contrast to protein expression, the highest of pde3b, pde4b, pde7a and pde8a genes in 
the CD4+ T cell fractions from HLN were at day 3 of AAD induction (Figure 2.2). Taken 
together, overall expression levels of pde3b, pde4b, pde7a and pde8a genes were 
higher during the acute AAD phase (day 3 or day 7 of the OVA challenge) than at the 
tolerance (day 42 of OVA challenge) stage of the disease model. 
 
Opposing effects of PDE8 and PDE4 inhibition on T cell adherence to endothelial 
cells in vitro 
Functionally, by using the inhibitor DP that inhibits a broad range of PDEs including 
PDE8 and the recently developed potent and highly PDE8-selective inhibitor PF-
04957325 (IC50 = 0.0007 µM for PDE8A and < 0.0003 µM for PDE8B), we 
demonstrated unique effects of PDE8 inhibition on adhesion and chemotaxis of 
activated T cells (24). PDE4 inhibition alone was ineffective in both assay systems. In 
previous experiments, we repeatedly detected a trend of increase of T cell blast 
adhesion to endothelial cells and chemotaxis when cells were treated with the highly 
selective and potent PDE4-selective inhibitor PICL. Therefore, we examined here the 
effect of combined inhibition of both the PDE4 and PDE8 families which has never been 
tested. As seen before, DP and PF-04957325 significantly inhibit T cell adhesion in 
these assays.  PF-04957325 had an inhibitory effect on T cell blast adhesion to the 
endothelial cell line b.End3 by 57% and 29% at 1 µM and 0.1 µM, respectively (Figure 
2.3) (*p<0.05, **p<0.001; one-way ANOVA and Bonferroni t-test).  Of note, DP and PF-
04957325 were the only compounds that significantly suppressed T cell adhesion.  In 
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contrast, the broad PDE inhibitor IBMX - which does not inhibit PDE8 – only marginally 
suppressed adhesion of activated T cells to b.End3 cell. Importantly, PICL, a highly 
potent PDE4 selective inhibitor, reversed the inhibitory effect of PF-04957325 at 1 µM 
from 57% to 21% when used in combination (Figure 2.3) (*p<0.05; one-way ANOVA 
and Bonferroni t-test).  These results clearly establish opposing effects, including partial 
reversal, of PDE8 versus PDE4 inhibition on rapid T cell adhesion in vitro, a conclusion 
which is additionally supported by PICL enhancing adhesion to 21% above the DMSO 
control when acting alone (Figure 3) (*p<0.05; one-way ANOVA and Bonferroni t-test). 
 
Differential potency of PDE8 and PDE4 inhibition on T cell proliferation in vitro 
and ex vivo 
Our results on adhesion are notable since in proliferation studies, PICL was significantly 
more efficient at suppressing Teff cell proliferation compared to PF-04957325 indicating 
a selective effect of PDE8 inhibition on rapid T cell adhesion to endothelial cells. To 
further probe the selectivity of PDE8 action in the control of T cell function, we examined 
the single and combined effect of broad and selective inhibitors on purified Teff cell 
proliferation in response to polyclonal or antigen-specific stimulation through the T cell 
receptor (TCR) (Figure 2.4). Isolated Teff cells were stimulated with immobilized anti-
CD3 mAbs in the presence of broad and selective PDE inhibitors over a range of 
concentrations alone and in combination in order to establish a dose-response. The 
PDE4-selective inhibitor PICL was over 100-times more effective in suppressing Teff 
cell proliferation than PF-04957325 (compare 1 µM PF-04957325 versus 0.01 µM PICL, 
Figure 2.4). There was a slight additional effect when both inhibitors were combined, 
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whereas the opposing effects seen in the adhesion assays (Figure 2.3) were not 
observed in any of the proliferation experiments (Figure 2.4). 
Additionally, we tested in vitro recall stimulation of T cells from lymph nodes of mice 
immunized with an encephalitogenic peptide, MOG35-55, of the myelin antigen MOG 
which is an autoantigen in EAE and MS (99, 100). In these assays, in contrast to 
experiments with anti-CD3 stimulation, antigen presenting cells are present during the 
entire experiment. As shown in Figure 2.5, proliferation was not inhibited by PF-
04957325 application in vivo (Figure 2.5 A) or in vitro (Figure 2.5 B). In contrast, PICL 
profoundly inhibited the proliferation in response to MOG35-55 in vitro (Figure 2. 5B), 
similar to the effect seen in anti-CD3 responses (Figure 2.4). 
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2.4 Discussion 
PDE enzymes are highly successful drug targets for treating vascular and inflammatory 
diseases (85, 91). The ability to form site- and function-specific cAMP gradients within 
the cell critically depends on its degradation by PDEs which are pivotal regulators of 
intracellular cAMP activity (19, 81-83). Observations that inhibition of PDE4, an 
abundantly expressed PDE in T cells, blocks T cell activation and function through 
elevating cAMP, prompted the development of PDE4 inhibitors as potential 
immunosuppressive therapies (21, 92, 93, 101, 102). After years of research and 
development of numerous candidate compounds, the FDA approval of the PDE4 
inhibitors roflumilast and apremilast in 2011 and 2014 for the treatment of COPD and 
psoriatic arthritis represent important breakthroughs for the use of PDE inhibitors in the 
therapy of human inflammatory disorders. Due to the limitations of PDE4 inhibitors set 
by their narrow therapeutic window, several alternative strategies are pursued to target 
PDEs in immune diseases. These include the inhibition of different cAMP-specific 
PDEs, such as PDE7 and PDE8. The recent development of the new PDE8 inhibitor 
PF-04957325 has helped to identify PDE8 as a novel target for suppression of effector 
T cell functions due to the important role of the PDE8 family in regulating cAMP 
signaling in these cells (91). After the initial observation that PDE8A is expressed in T 
cells, several reports documented the role of PDE8 in controlling T cell and cancer cell 
motility (23, 24, 32, 33, 79). Together, PDE7 and PDE8 are now seen as new emerging 
targets to treat inflammation (91).  Our data demonstrate for the first time robust PDE8A 
expression in leukocytes associated with an inflammatory disease in vivo, a mouse 
model of AAD. The preferential expression of PDE8A protein in the CD4+ T cell subset 
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during the acute AAD stage and its subsequent recession in the non-inflammatory 
tolerant stage, together with the common assumption that CD4+ Teff cells are a major 
contributor to the development of AAD in animals and asthma in humans, strengthen 
the case to further examine PDE8A inhibition in preclinical and clinical studies of 
inflammatory disorders, including human respiratory airway diseases.  
 
Previously, we failed to detect any suppressive effect of the highly potent PDE4-
selective inhibitor PICL on T cell adhesion to activated endothelial cells. In contrast, DP 
reduced adhesion of T cell blasts by 73% while PF-04957325 reduced adhesion by a 
maximum of 53%. However, PICL was also very efficient at suppressing proliferation. 
Thus, our data suggest that a rapid effect on T cell adhesion critically depends on a 
PDE inhibitor that blocks PDE8 enzymatic activity, while inhibition of Teff cell 
proliferation is less dependent on blocking the PDE8 isoform. In this present study, we 
explored the precise action of PDE8 and PDE4 selective inhibition of T cell adhesion by 
testing inhibitors over a range of concentrations and in combination. In doing so, we 
found an entirely novel effect of PDE4 inhibition enhancing adhesion of T cells to 
endothelial cells and opposing the inhibitory effect of PDE8 inhibition. These data 
suggest distinct signaling pathways utilized by PDE8 and PDE4 in T cells, a hypothesis 
further supported by the differential action of selective inhibitors of these enzymes in 
proliferation assays. 
 
At present, it is unknown what accounts for the different effects of selected PDE isoform 
inhibition during adhesion and proliferation. Regulation of adhesion of leukocytes to 
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vascular endothelial ligands is a very fast process measured in microseconds (6). A 
possible mechanism may be that DP and PF-04957325 upregulate intracellular cAMP 
levels more rapidly and efficiently than PDE inhibitors that do not block PDE8, requiring 
a longer time of action for less efficient PDE inhibitors during Teff cell adhesion (103). 
Since PDE8A is a very high affinity cAMP-specific PDE with a Km value ranging from 
0.04-0.15 µM, 40-100 times lower than that of PDE4, it is likely to be functioning at 
lower cAMP concentrations than PDE4 and may thus be involved in the control of 
intracellular cAMP concentrations at basal levels and in the immediate response to 
acute increases of cAMP in specific cell regions (34, 38, 104). This mechanism would 
be consistent with our data. Major mechanistic insights into PDE8A signaling came from 
a recent report that PDE8A associates with Raf-1 to protect it from inhibitory 
phosphorylation by PKA (46). Raf kinases have been shown to regulate integrin α4β1-
mediated T cell resistance to shear stress which may explain our observations in T cell 
adhesion assays (105). 
 
We also analyzed the effects of PF-04957325 administration on CD4+ responses in 
draining lymph nodes 10 days after MOG35-55 and CFA immunization. We found no 
effect of PF-04957325 administered s.c. on CD4+ Teff cell proliferation (Figure 5) or 
production of IFN-γ or IL-17, nor changes in percentage and numbers of CD4+, Foxp3+ 
(Treg cells), γδTCR+ or Ki-67+ (proliferating) T cells in the draining lymph nodes of CFA 
and MOG35-55 immunized mice (data not shown). Additionally, in contrast to the PDE4-
selective inhibitor PICL, PF-04957325 did not significantly suppress T cell proliferation 
in vitro in response to MOG35-55 and showed over 100-times lower efficacy in 
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suppressing proliferative responses to anti-CD3 stimulation. The different potency of 
PF-04957325 in assays using whole lymph nodes could indicate a role for costimulation 
provided by antigen-presenting cells overcoming its moderate anti-proliferative action 
when isolated Teff cell proliferation were stimulated by anti-CD3 mAb. Overall, our 
results indicate a non-redundant role for PDE8 in regulating T cell adhesion to vascular 
endothelium through the cAMP signaling pathway. The data further suggest that PDE8 
inhibition, if successful in vivo in inflammatory diseases, may selectively target 
leukocyte motility without exerting global immunosuppressive effects on cytokine 
production and cell proliferation and thus provide a highly selective therapeutic tool 
while maintaining the proven characteristics of PDE inhibitors as successful drugs. 
Taken together, efforts to develop and test selective inhibitors of PDE8 such as PF-
04957325 should be undertaken as a means to develop novel therapeutic agents for 
treatment of inflammatory disorders mediated by activated T cells (106-110).
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2.5 Materials and Methods 
 
Animals  
6-12 week old female C57BL/6 mice were from Jackson Laboratories (Bar Harbor). 
Female mice are widely used in experimental allergy and autoimmunity models, and we 
used them to keep consistency with previous studies (111, 112).  Experiments were 
performed according to approved protocols at UConn Health (IACUC Protocol number 
100794). 
 
Bi-phasic model of OVA-induced AAD 
For the induction of OVA-induced AAD mice were: 1) sensitized to 25 µg OVA in the 
adjuvant alum with 3 intraperitoneal injections, 1 week apart; 2) one week after the last 
immunization, mice in each group were exposed to 1% aerosolized OVA in 
physiological saline (one hour/day, 5 days a week until sacrifice) with an estimated 
inhaled daily dose of 30–40 µg/mouse as described previously (111, 113, 114). Groups 
of mice (5/group) were sacrificed at 3, 7, and 42 days post start of daily aerosolization. 
Mice sacrificed at 3 and 7 days represent AAD (peak inflammation) and those at 42 
days represent resolution of AAD and the development of tolerance.  At sacrifice, the 
lung draining hilar (mediastinal) lymph node (HLN) and peripheral inguinal lymph nodes 
(ILN) were dissected and further processed as described below. This bi-phasic model 
enables us to study the expression of PDE8A during and after acute inflammation. 
Induction of OVA-induced AAD was done by Linda Guernsey. 
 
Myelin oligodendrocyte glycoprotein (MOG) peptide MOG35-55  
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MOG35-55 peptide, corresponding to mouse sequence 
(MEVGWYRSPFSRVVHLYRNGK) was synthesized and purified by the Yale University 
Synthesis Facility. 
 
Immunization of mice with MOG35-55 peptide 
6 - to 12-wk-old mice were immunized with MOG35-55 in Complete Freund’s Adjuvant 
(CFA; Sigma-Aldrich), a procedure to induce experimental autoimmune 
encephalomyelitis (EAE) in C57BL/6 mice, an animal model of multiple sclerosis (MS) 
(99). A total of 200 µg of MOG35-55 peptide and 400 µg of killed Mycobacterium 
tuberculosis (Difco Laboratories) was emulsified in CFA and injected s.c. into the 
footpads of mice. 
 
Cell isolation and activation   
In the AAD model, lymph node cells (LNC) from HLN and ILN were processed using 
CD4+ T cell isolation kits (Miltenyi Biotec) to separate CD4+ from CD4- cell populations. 
LNC were also dissected from draining popliteal lymph nodes after s.c. immunization 
with MOG35-55 peptide, an autoantigen recognized by T cells in EAE and MS (99). 
Concanavalin A (Con A) activated mouse splenocytes as a source of T cell blasts were 
prepared and cultured as described (24, 32). Cells were either immediately frozen in 
appropriate reagents for subsequent qRT-PCR or Western immunoblot analyses or 
used in proliferation assays as described (79).  
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RNA isolation and cDNA synthesis 
RNA from cells was isolated using the RNeasy mini kit and treated with Turbo DNA-free 
Dnase (Ambion). cDNA was synthesized using Superscript III reverse transcriptase 
(Invitrogen) (24, 79).  
 
Quantitative real-time RT-PCR analysis 
Quantitative real-time RT-PCR (qRT-PCR ) was performed as described previously (24, 
79). 10 ng cDNA was amplified by qRT-PCR in a 25µl reaction using SYBR Green PCR 
Master Mix (Applied Biosystems). Primers were designed using Primer Express 
software v3.0. Primers were chosen from gene regions common to all known splice 
variants of a specific gene product. Primer efficiency was verified by slope analysis to 
be 100% ± 2.5%. qRT-PCR was performed using an ABI 7500 fast system and data 
analyzed using the ∆ct method (SDS software v3.0). Primer sequences and amplicon 
sizes were published previously (24, 79). Expression data were normalized by 
calculating the ratio of target gene expression/housekeeping gene rpl19 expression. 
 
Western immunoblot analysis 
Western immunoblot analysis was performed as described previously (79, 80)((53). 
Mouse T cells were centrifuged at 300 x g for 5 min, washed twice with ice-cold PBS, 
and lysed in RIPA buffer with 1:100 protease inhibitor cocktail (Sigma). Protein 
concentration was determined using a BCA Protein Assay Kit (Pierce). Equal amounts 
of protein were loaded and run on 10% SDS-PAGE gels.  Proteins were then 
transferred onto Immobilon-P transfer membrane (Millipore).  Membranes were blocked 
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with 5% BSA in Tris-buffered saline for 1 h at room temperature and probed with 
primary antibodies overnight at 4° C. Specificity and source of antibodies directed 
against PDE gene families and isoforms were published previously (79). After probing, 
membranes were washed three times with TBS-T buffer, and incubated with 
horseradish peroxidase-conjugated secondary antibody (Anti-Rabbit IgG-horseradish 
peroxidase was obtained from GE Healthcare) at a final dilution of 1:5000 and then 
washed three more times. Proteins were visualized and quantitated with SuperSignal 
West Femto Maximum Sensitivity Substrate (Pierce) using Syngene G:Box with 
GeneSnap BioImaging software. Staining with anti-GAPDH antibody (Abcam) was used 
for loading control and the signal was used for normalization in quantitation by 
determining the ratio of the target protein band density/GAPDH band density for CD4+ 
cells divided by the target protein band density/GAPDH band density for the CD4- cell 
population. 
 
Adhesion assays 
Adhesion assays were performed in 24-well plates with a confluent layer of activated 
cells of the murine brain endothelium-derived cell line bEnd.3 (ATCC). 100 µM DP, 300 
µM IBMX, 1 and 0.1 µM PICL, or PF-04957325 were added to bEnd.3 cells for the last 
45 min of TNF-α incubation. T cell blasts or Teff cells were labeled with 5 µM Calcein 
AM (Molecular Probes) and treated as described above. 7 x 105 pretreated T cell blasts 
or Teff cells per well were incubated on bEnd.3 cells in RPMI media. After 30 min at 
37ºC, non-adherent cells were removed by washing with D-PBS. For analysis, 7 x 105 
Calcein AM labeled T cell blasts or Teff cells were used as positive controls. 
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Fluorescence was read in a Victor 3v microplate reader (Perkin Elmer) with a 
fluorescein filter set. The percentage of labeled cells resistant to detachment was 
calculated as total fluorescence of well divided by fluorescence of 7 x 105 Calcein AM 
labeled cells. 
 
Proliferation assays 
Isolated Teff cells (5 x 104/well) were cultured in round bottom 96-well plates (Costar) in 
the presence or absence of soluble anti-CD3 mAb (0.7 µg/ml; R&D). PICL (1, 0.1, 0.01 
µM), PF-04957325 (1, 0.1, 0.01 µM), alone or in combination, or vehicle control (0.1% 
DMSO in media) were added at 0 h (79). Proliferation of popliteal LNC in reponse to 
MOG35-55 peptide with inhibitors or vehicle control was performed in round bottom 96-
well plates (Costar) at a concentration of 2 x 105 cells/well. After 48 h, 2 µCi per well of 
[3H]thymidine (NEN) was added and cells were harvested 16 h later using a 
semiautomated cell harvester. [3H]thymidine incorporation was determined by 
scintillation counting.  
 
Statistics 
Experimental groups were compared by analyzing data with the Student's unpaired t-
test or one-way ANOVA followed by Bonferroni t-test using SigmaStat and GraphPad 
software. Probability levels for statistically significant differences are indicated by the p-
value in the figure legend and by corresponding asterisks in the figures (*p < 0.05, **p < 
0.001).  
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Figure 2.1 
 
Figure 2.1. Differential expression of PDE8A isoforms in CD4+ and CD4- leukocyte 
populations localized in the HLN of mice with OVA-AAD in vivo. PDE expression 
was analyzed by Western immunoblot in ex vivo isolated HLN (A, B) and ILN (C, D) 
cells from mice with AAD. LNCs were separated into CD4+ and CD4- populations by 
magnetic bead isolation. A (HLN) and C (ILN) show a comparison of PDE8A protein 
expression at day 3, 7 and 42 AAD between the CD4+ T cell and CD4- leukocyte 
subpopulations and GAPDH as a loading control for each immunoblot. The data shown 
are immunoblot analyses from pooled LNCs from 5 HLN that were separated into CD4+ 
and CD4- populations for each day of the experiments. B (HLN) and D (ILN) show 
abundance of PDE8A protein determined by immunoblot densitometry and normalized 
to GAPDH expression. The figure shows the mean + SEM of the quantification of results 
from HLN samples from day 3, day 7 and day 42 AAD performed in 2 independent 
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experiments (n = 5 mice per group, 2 groups per day, total n = 30 mice) as the ratio of 
the target protein band density/GAPDH band density for CD4+ cells divided by the target 
protein band density/GAPDH band density for the CD4- cell population.  
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Figure 2.2 
 
Figure 2.2. Pde3b, pde4b, pde7a and pde8a gene expression in CD4+ T cells 
localized in the draining HLN of mice at various days of OVA exposure in vivo. 
PDEs were analyzed by qRT-PCR in ex vivo isolated HLN cells from mice with AAD 
separated into CD4+ and CD4- cell populations. Data are normalized and expressed as 
the ratio mean + SEM of target gene expression/housekeeping gene rpl19 expression. 
Data in (A) show a comparison of pde3b gene expression in CD4+ cells of HLN samples 
from day 3, day 7 and day 42 AAD (n = 3). Data in (B) show pde4b gene expression, in 
(C) pde7a gene expression and in (D) expression of pde8a in CD4+ cells of HLN in AAD. 
(n = 5 mice per group, total n = 15 mice; *p < 0.05, **p < 0.001, unpaired t-test).  
Experiment performed by Dr. Amanda G. Vang and Rebecca Nguyen. 
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Figure 2.3 
 
Figure 2.3. Inhibiting PDE8 suppresses Teff cell adhesion to endothelial cells and 
is reversed by PDE4 inhibition. T cell blasts from C57BL/6 mice and bEnd.3 
endothelial cells were incubated alone or in combination with IBMX (300 µM), PICL (1 or 
0.1 µM), DP (100 µM) or PF-04957325 (1 or 0.1 µM). Values are normalized to the 
vehicle condition (0.1% DMSO) and presented as the mean + SEM percentage of T cell 
blasts resistant to detachment. Data are averages from three to four independent 
experiments performed in triplicate (*p < 0.05, **p < 0.001, one-way ANOVA and 
Bonferroni t-test). Experiment performed by Dr. Amanda G. Vang. 
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Figure 2.4. Selective inhibition of Teff cell proliferation by PDE4 inhibition in vitro. 
Proliferation of purified CD4+CD25- Teff cells exposed to PDE inhibitors. Teff cells (5 x 
104/well) were cultured with immobilized anti-CD3 mAb or control in the presence of 
IBMX (300 µM), DP (100 µM), PICL, PF-04957325 alone or in combination, or vehicle 
control (0.1% DMSO). The extent of proliferation was determined by [3H]thymidine 
incorporation at 64 h and results are presented as mean + SEM counts per min (cpm). 
Data are representative of three to five independent experiments performed in triplicate 
(*p < 0.05, **p < 0.001, comparisons to vehicle were analyzed using a one-way ANOVA 
and Bonferroni t-test). Experiment performed by Dr. Stefan Brocke and Dr. Robert B. 
Clark.	  
Figure	2.4	
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 Figure 2.5 
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Figure 2.5. PF-04957325 does not suppress T cell proliferation in response to 
MOG35-55 ex vivo and in vitro. (A) C57BL/6 mice were immunized with MOG35-55 and 
CFA and treated twice daily from day 8-10 by subcutaneous administration of PF-
04957325 (PF1, PF2) or vehicle control (V1, V2) (n = 2 mice per group, total n = 4). 
Each injection contained a dose of 2.5 mg/kg PF-04957325 dissolved in 100 µl vehicle 
(PF-04957325) or 100 µl vehicle alone (vehicle control). (B). C57BL/6 mice were 
immunized with MOG35-55 and CFA (n = 2). (A, B) Draining popliteal lymph nodes were 
dissected 10 day after immunization and an in vitro proliferation assay was performed 
under conditions as indicated. MOG35-55 (50 µg/ml) was present where indicated (A, B), 
together with PDE inhibitors in vitro as shown (B). Experiment performed by Dr. Stefan 
Brocke and Dr. Robert B. Clark. 
 
 
 
 
 
 
 
 
 
 
 
 
 	 	 	 	 	45	
Chapter 3 
PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling 
complex 
3.1 Summary 
The levels of cAMP are regulated by phosphodiesterase enzymes (PDEs), which are 
targets for the treatment of inflammatory disorders. We have previously shown that 
PDE8 regulates T cell motility. Here, for the first time, we report that PDE8A exerts its 
control of T cell function through the Raf-1 kinase signaling pathway. To examine T cell 
motility under physiologic conditions, we analyzed T cell interactions with endothelial 
cells and ligands in flow assays. The highly PDE8-selective enzymatic inhibitor PF-
04957325 suppresses adhesion of in vivo myelin oligodendrocyte glycoprotein (MOG35-
55) activated inflammatory CD4+ T effector (Teff) cells to brain endothelial cells under 
shear stress. Recently, PDE8A was shown to associate with V-raf-1 murine leukemia 
viral oncogene homolog 1 (Raf-1) creating a compartment of low cAMP levels around 
Raf-1 thereby protecting it from protein kinase A (PKA) mediated inhibitory 
phosphorylation. To test the function of this complex in Teff cells, we used a cell 
permeable peptide that selectively disrupts the PDE8A-Raf-1 interaction. The disruptor 
peptide inhibits the Teff–endothelial cell interaction more potently than the enzymatic 
inhibitor. Furthermore, the LFA-1/ICAM-1 interaction was identified as a target of 
peptide mediated reduction of adhesion, spreading and locomotion of Teff cells under 
flow. Mechanistically, we observed that inhibition of PDE8 and disruption of the PDE8A-
Raf-1 complex profoundly alter Raf-1 signaling in Teff cells. Collectively, our studies 
demonstrate that PDE8A inhibition by enzymatic inhibitors or PDE8A-Raf-1 kinase 
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complex disruptors decreases Teff cell adhesion and migration under flow, and 
represents a novel approach to target T cells in inflammation. 
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3.2 Introduction 
Ligand binding to Gs-coupled receptors leads to the generation of the second 
messenger cAMP following activation of the enzyme adenylyl cyclase. Stimulation of the 
T cell antigen receptor (TCR) also leads to elevation of cAMP which is known to inhibit 
T cell proximal signaling, IL-2 production and T cell proliferation (115). cAMP exerts 
these inhibitory effects in T cells through the PKA (cAMP dependent protein kinase) 
which blocks the MAPK (mitogen- activated protein kinase) and NFAT (nuclear factor of 
activated T cells) dependent signaling pathways (116). The inhibitory action of cAMP is 
eliminated through the action of phosphodiesterase (PDE) enzymes that hydrolyze 
cAMP. PDEs 3B, 4A, 4B, 4D, 7A1, 7A3 and 8A1 are the isoforms expressed in T cells 
(15, 23, 24, 44). Raf-1 is an upstream regulator of the mitogen-activated protein kinase 
(MAPK) – ERK1/2 module, which controls many fundamental biological processes, 
including T cell proliferation, survival and adhesion (117-120). In this pathway Raf-1 
phosphorylates and activates MEK1/2, which in turn phosphorylate and activate 
ERK1/2. ERK has more than 150 known substrates (117, 120), which mediate many of 
the pleiotropic functions of this pathway (121, 122). Raf-1 regulation is complex and is 
still insufficiently understood. Critical events are the dephosphorylation of an inhibitory 
site, S259, which allows Raf-1 binding to activated rat sarcoma viral oncogene (Ras) 
and is a prerequisite for further activation. S259 is a target for phosphorylation by cAMP 
dependent protein kinase A (PKA) (51, 123, 124), a family of enzymes whose activity is 
dependent on local intracellular levels of cAMP. Thus, S259 is the primary target of a 
complex system of crosstalk between the cAMP and the ERK pathways. A recent report 
demonstrated that Raf-1 kinase binds to PDE8A in a signaling complex, which acts to 
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protect Raf-1 from inhibitory phosphorylation by PKA (43, 46, 125). Our previous work 
has shown that PDE8 controls T cell and breast cancer cell motility (24, 32, 33, 79). 
PDE8 is also a target for suppression of myelin oligodendrocyte glycoprotein (MOG35-55) 
induced experimental autoimmune encephalomyelitis (EAE), a model for multiple 
sclerosis, in vivo (unpublished). Our goal here was to delineate the mechanism by 
which PDE8 controls distinct categories of T cell motility and determine its selective 
effect on regulatory and effector components of the T cell immune response.  
 
Our recent work shows that CD4+ T cells isolated from the lung draining hilar lymph 
nodes have increased PDE8A expression during the acute inflammatory stage in an 
ovalbumin induced allergic airway disease mouse model (126). This further emphasizes 
the concept of targeting PDE8A in inflammation. Recently, there has been a surge of 
interest in the cAMP specific PDE8 family of enzymes. PDE8 is expressed widely in 
human tissue (127) with functions in testosterone production (104) and lymphocyte 
adhesion and chemotaxis (24, 32, 33, 79). T cell activation induces PDE8A, a cAMP-
specific PDE with 40-100-fold greater affinity for cAMP than PDE4 (23, 32). This unique 
feature has led to the suggestion that PDE8 enzymes may have an important role in 
protecting any associated protein from being affected by fluctuations in basal cAMP 
concentrations. Compartmentalization of PDE8A in the cell to Raf-1 can regulate Raf-1 
phosphorylation on S259, and, in so doing, regulate the cross-talk node whereby cAMP 
exerts an inhibitory effect on Raf-1 signaling, retarding subsequent ERK 
phosphorylation and potentially T cell activation (43, 46).  
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Based on these observations, we hypothesized that PDE8A exerts its regulation of T 
cell function through the Raf-1-ERK signaling pathway. Little is known regarding the 
specific functions of PDE8A within the immune system, especially whether the control of 
T cell motility is mediated through different effectors of the canonical Raf-1-ERK 
signaling cascade. B-Raf has been demonstrated to regulate VLA-4 integrin mediated 
adhesion in human T cells under shear stress (105). Here, we probed the PDE8A-Raf-1 
kinase signaling pathway in Teff and regulatory T (Treg) cells, using specific 
pharmacological tools including PDE8 inhibitors and peptide disruptors of the PDE8A-
Raf-1 complex in adhesion assays under flow to assess the molecular regulation of 
downstream effectors of the PDE8A-Raf-1 complex. 
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3.3 Results 
Differential motility of naive and activated Teff and Treg cells under flow.  
Since PDEs and cAMP levels significantly differ between Teff and Treg cells (79, 128), 
we first tested CD4+CD25- Teff and CD4+CD25+ Treg cells under naive and activating 
conditions for their ability to interact with LPS-activated endothelial cells (ECs) under 
shear flow. Mouse brain ECs were cultured as a monolayer, stimulated with LPS 
overnight, and the subsequent adhesive interactions with ECs were measured in the 
flow chamber assay. Compared to naive Teff cells, naive Treg cells showed 17.8 ± 
3.7% higher adhesion (11.1 ± 3.1% vs. 28.9 ± 2.0%, **p=0.0031) (Fig. 1A) while 
interacting with the EC monolayer. These findings are similar to previous reports 
indicating that naive Teff cells have lower adhesion potential compared to naive Treg 
cells (129). Activation via their T cell receptor (TCR)/CD3ε led to a 7.7 ± 4.5% 
(p=0.1287) increase in adhesion in Teff cells (18.8 ± 3.1%) and 13.8 ± 3.9% (**p=0.006) 
decrease in adhesion of Treg cells (15.1 ± 2.6%) compared to their naive counterparts. 
Addition of IL-2 along with TCR activation further increased adhesion of Teff cells (24.1 
± 2.4%) by 13.0 ± 4.0% (*p=0.01) and restored adhesion of Treg cells (25.7 ± 7.9%) 
(p=0.7415). Thus under naive conditions Treg cells are highly motile and activation in 
the absence of IL-2 led to a decrease in their migratory potential (Fig. 1A). We 
confirmed these findings using transgenic Foxp3gfp.KI mice in which Teff and Treg cells 
were isolated using a combination of a CD4+ T cell isolation kit and cell sorting by flow 
cytometry based on GFP expression (Fig. 1B). Foxp3-GFP- Teff cells sorted from these 
mice had significantly lower (5.5 ± 2.0%) TEM potential compared to Foxp3+GFP+ Treg 
cells (1.5 ± 0.9% vs. 7.0 ± 2.1%, *p=0.0422) after TCR stimulation (Fig. 1C). Foxp3-
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GFP- Teff cells have a 22.5 ± 9.1% higher detachment compared to Foxp3+GFP+ Treg 
cells (74.9 ± 6.6% vs. 52.4 ± 5.5%, p=0.0571) (Fig 1D). This differential migratory 
potential of Teff cells and Treg cells prompted us to study whether PDE8 inhibition using 
the PDE8 inhibitor PF-04957325 will show a differential effect on motility of Teff versus 
Treg cells. 
 
PDE8 inhibition at the catalytic moiety leads to decreased adhesion of Teff cells 
but not Treg cells under shear flow conditions.  
We have previously shown that PDE8A is differentially expressed in naive Teff cells 
versus naive Treg cells (79). We now examined whether different expression levels of 
PDE8A can also be detected in pathogenic T cell populations involved in autoimmune 
inflammation. Our data show that CD4+CD25- Teff cells isolated from draining lymph 
nodes of MOG35-55 immunized mice had higher expression of PDE8A and Raf-1 
compared to CD4+CD25+ Treg cells (Fig. 2A,B). Next, we used Foxp3gfp.KI mice 
immunized with MOG35-55 to determine the effect of PDE8 inhibition on activated, 
pathogenic T cells. This approach enabled us to visually distinguish Teff and Treg cells 
and simultaneously measure the effect of inhibitors on Teff and Treg cells within the 
same experiment. PDE8 inhibition using PF-04957325 led to a significant decrease in 
adhesion (100.0% vs. 63.3 ± 6.9%, **p=0.0019), and an increase in detachment 
(100.0% vs. 117.9 ± 7.4%, p=0.0510) of CD4+Foxp3-GFP- Teff cells compared to 
vehicle control treatment (Fig. 2C). No significant effect was observed on adhesion 
(100.0% vs. 108.6 ± 26.1%, p=0.7536) and detachment (100.0% to 105.2± 9.1%, 
p=0.5850) of CD4+Foxp+GFP+ Treg cells after PDE8 inhibition (Fig. 2D). The observed 
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difference in PDE8A abundance between Teff and Treg cells could explain the 
differential effect of PDE8 inhibition on Teff cells vs. Treg cells.  
 
Disruption of PDE8A-Raf-1 kinase signaling complex suppresses Teff and Treg 
cell adhesion. 
PDE8A has been shown to interact with Raf-1 kinase without the need for accessory 
proteins or lipids and protect it from PKA mediated inhibitory phosphorylation. The Raf 
family members have been known to regulate adhesion of T cells to vascular ligands 
(105) We next used a cell permeable peptide that disrupts the PDE8A-Raf-1 interaction 
(46) to determine whether this complex regulates CD4+ T cell motility under flow 
conditions. CD4+ T cells isolated from draining lymph nodes of MOG35-55 immunized 
Foxp3gfp.KI mice and endothelial cells were treated with cell permeable disruptor or 
control peptides for 4 h. Treatment with the disruptor peptide decreased adhesion of 
CD4+GFP-Foxp3- Teff cells by 43.6 ± 14.3%, (100.0% vs. 56.4 ± 14.3%, *p= 0.0221) 
and increased detachment by 9.7 ± 6.6% (100.0% vs. 109.7 ± 6.6%, p=0.1919) (Fig.3A) 
compared to control. We also observed 39.1 ± 24.3% decrease in adhesion of 
CD4+GFP+Foxp3+ Treg cells, but this difference was not significant (100.0% vs. 60.9 ± 
24.3%; p=0.1590) and a 7.8 ± 6.0% increase in Treg cell detachment (100.0% vs. 107.8 
± 6.0%, p=0.2417) (Fig. 3B). 
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Adhesion, spreading and locomotion of Teff cells to ICAM-1 are significantly 
affected by disruption of PDE8A-Raf-1 complex, but not by PDE8 inhibition at the 
catalytic moiety.  
Next, we assessed whether PDE8 or the PDE8A-Raf-1 kinase complex regulate 
adhesion via LFA-1 integrin mediated cell tether formation with ICAM-1. For this 
purpose, we tested interaction of CD4+ T cells on plates coated with recombinant ICAM-
1-Fc protein under shear flow conditions. Treatment of CD4+ T cells with PF-04957325 
did not lead to significant differences in CD4+GFP-Foxp3- Teff cell mediated transient 
tethers (100.0% vs. 112.8 ± 53.0%, p=0.8213), firm tethers (100.0% vs. 99.8 ± 9.6%, 
p=0.9809), spreading (100.0% vs. 66.0 ± 28.8%, p=0.3038), locomotion (100.0% vs. 
62.6 ± 29.6%, p=0.2744), detachment (100.0% vs.103.6 ± 2.3%, p=0.1944) (Fig. S1A), 
or adherence (100.0% vs. 68.6 ± 15.4%, p=0.1120) when ICAM-1 was used as a 
substrate in flow assays (Fig. 4A). There was also no significant effect of PF-04957325 
treatment on CD4+GFP+Foxp3+ Treg cell mediated firm tether formation (100.0% vs. 
90.0 ± 13.2%, p=0.4916), adherence (100.0% vs. 191.5 ± 83.5%) or detachment 
(100.0% vs. 88.0 ± 6.7%, p=0.1498) (Fig. S1B). In contrast, treatment with the PDE8A-
Raf-1 disruptor peptide led to a significant 52.6 ± 13.3% decrease in CD4+GFP-Foxp3- 
Teff cell adherence, (100.0% vs. 47.4 ± 13.3%, *p=0.0167), a significant 59.3 ± 4.3% 
decrease in spreading (100.0% vs. 40.7 ± 4.3%, *** p=0.0002) and a significant 72.7 ± 
4.6% decrease in locomotion, (100.0% vs. 27.3 ± 4.6%, ****p < 0.0001) (Fig. 4B), but no 
significant effect was observed on transient tethers (100.0% vs. 150.8 ± 95.9%, 
p=0.6240), firm tethers (100.0% vs. 60.3 ± 23.3%, p=0.1634) and detachment (100.0% 
vs. 106.1 ± 3.6% p=0.1688) of Teff cells when ICAM-1 was used as a substrate (Fig. 
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S1C). Of note, there was also a significant 43.3 ± 13.1% decrease in adherent cell 
tethers of CD4+GFP+Foxp3+ Treg cells interacting with ICAM-1 (100.0% vs. 56.7 ± 
13.1%, *p=0.0299) after treatment with the disruptor peptide (Fig. 4C). No significant 
effect on firm tether formation (100.0% vs. 65.5 ± 25.3%, p=0.2450) and detachment 
(100.0% vs. 112.9 ± 9.3%, p=0.2358) of Treg cells was observed (Fig. S1D). These 
data implicate the LFA-1-ICAM-1 interaction as a target of PDE8A-Raf-1 kinase 
complex disruption. 
 
CD4+ T cell mediated firm cell tether formation to VCAM-1 is unaffected by 
disruption of PDE8A-Raf-1 complex and PDE8 inhibition at the catalytic moiety. 
To further explore whether the effect of the PDE8 inhibitor or the PDE8A-Raf-1 complex 
disruptor peptide on adhesion of CD4+ T cells was dependent on the integrin VLA-4, we 
tested binding of cells to its selective ligand, VCAM-1 under flow (130). No significant 
differences were observed in transient tethers, (100.0% vs. 196.1 ± 81.9%, p=0.2849), 
rolling (100.0% vs. 87.6 ± 23.8%, p=0.6204), firm tethers (100.0% vs. 134.7 ± 36.6%, 
p=0.3805), adherence (100.0% vs. 127.9 ± 48.8%, p=0.5881) and detachment (100.0% 
vs. 99.8 ± 0.6%, p=0.7070) in CD4+ T cell interaction with VCAM-1 after treatment with 
PDE8 inhibitor (Fig. S2A). Treatment with disruptor peptide did not have any significant 
effect on transient tethers (100.0% vs. 90.4 ± 22.7%, p=0.6860), firm tethers (100.0% 
vs. 81.2 ± 13.3%, p=0.2074), adherence (100.0% to 69.5 ± 23.4%, p=0.2402) and 
detachment (100.0% vs. 102.5 ± 1.7%, p=0.1967). However, there was a significant 
56.4 ± 7.3% suppression of rolling (100.0% vs. 43.6 ± 7.3%, **p=0.0015) after treatment 
 	 	 	 	 	55	
with the disruptor peptide, indicating a selective effect of the peptide on initial loose 
tethers of T cells to VCAM-1 (Fig. S2B).  
 
Integrin surface expression in CD4+ T cells is not altered by PDE8 inhibition at the 
catalytic moiety and marginally reduced by disruption of the PDE8A-Raf-1 
complex. 
α4 and αL integrins as well as CD44 are known cell surface molecules regulating myelin 
antigen specific Teff cell migration into the central nervous system (10, 11) and are 
targets of drug therapies (131). We tested the effect of the PDE8 inhibitor and the 
disruptor peptide on the surface expression of these adhesion molecules by flow 
cytometry. PF-04957325 treatment did not significantly alter the mean fluorescence 
intensity (MFI) of αL integrin (p=0.2608), α4 integrin (p=0.1053) or CD44 (p=0.3675) in 
CD4+Foxp3-GFP- Teff cells (Fig. S3A) or CD4+GFP+Foxp3+ Treg cells (p=0.5396; 
p=0.0677; p=0.0899, respectively; Fig. S3B). In contrast, there was a small but 
significant 2830 ± 645.8 unit decrease in the MFI of αL integrin expression (30957 ± 
350.1 vs. 28127 ± 542.7, *p=0.0119) and a 259.7 ± 65.19 units decrease in MFI of 
CD44 expression (3453 ± 55.98 vs. 3194 ± 33.39, *p=0.0164) but not in MFI of α4 
integrin (p=0.3814) in CD4+Foxp3-GFP- Teff cells after treatment with the disruptor 
peptide (Fig. S3A). Disruptor peptide treatment did not significantly alter MFI of αL 
integrin (p=0.1025), α4 integrin (p=0.8069) or CD44 (p=0.0573) in CD4+GFP+Foxp3+ 
Treg cells. Of note, PF-04957325 and disruptor peptide treatments did not affect the 
viability of CD4+ T cells (Fig. S4) 
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PDE8 inhibition at the catalytic moiety significantly suppresses ERK 
phosphorylation in CD4+ T cells activated by anti-CD3.  
To find out whether the effect of the PDE8 and PDE8A-Raf-1 complex inhibition on 
CD4+ T cell motility directly affects Raf-1 or ERK signaling, we performed assays to 
determine inhibitory phosphorylation of Raf-1 at S259 and activating phosphorylation of 
ERK1/2 after treatment and activation through the TCR. ERK1/2 phosphorylation 
(Thr202/Tyr204) and Raf-1 phosphorylation (S259) was analyzed by Western blot (Fig. 
5). We observed no significant effect on Raf-1 phosphorylation (100.0% vs. 104.3 ± 
7.2%, p=0.5937), but a significant 36.2 ± 6.8% decrease in ERK1 phosphorylation 
(100.0% vs. 63.8 ± 6.2%, ***p=0.0002) and a significant 27.9 ± 9.366% decrease in 
ERK2 phosphorylation (100.0% vs. 72.1 ± 8.6%, *p=0.0125) in CD4+ T cells after 1 h 
treatment with PF-04957325 compared to the vehicle control (Fig. 5A,B). These results 
indicate that the PDE8 enzyme regulates in part the ERK1/2 signaling pathway. We also 
report that inhibition of PDE8 enzymatic activity led to a 71.4 ± 25.8% compensatory 
increase in PDE8A protein expression, (100.0% vs. 171.4 ± 23.7%, *p=0.0183) (Fig. 
5C-D). Augmentation of PDE7A, PDE4B and PDE4D expression after treatment with 
cAMP elevating agents or gene family specific PDE inhibitors has been reported before 
(132, 133), and we show here that this occurs with PDE8A as well.  
 
Disruption of the PDE8A-Raf-1 complex increases inhibitory Raf-1 
phosphorylation and activating ERK1/2 phosphorylation in CD4+ T cells activated 
by anti-CD3. 
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Treatment with the PDE8A-Raf-1 disruptor peptide for 4 h followed by 15 min anti-CD3 
stimulation, led to a 134.7 ± 59.99% (100.0% vs. 234.7 ± 59.99%, p=0.0549) increase in 
PKA mediated inhibitory Raf-1 phosphorylation at S259 (Fig. 6A). Additionally, there 
was a 134.1 ± 57.22% increase at 4 h (100.0% vs. 234.1 ± 50.46%, p=0.0516) in 
activating ERK1 phosphorylation and a 131.4 ± 64.14% increase at 4 h (100.0% vs. 
231.4 ± 56.57%, p=0.0797) in activating ERK2 phosphorylation in CD4+ T cells exposed 
to the disruptor peptide (Fig. 6B). Since in flow assays the CD4+ T cells were treated 
with the peptide for 4 h, our data indicate that the major effect of the PDE8A-Raf-1 
complex is dependent on Raf-1 signaling independent of the downstream ERK-MAPK 
pathway. Despite this robust effect on inhibitory Raf-1 phosphorylation, treatment with 
the PDE8A-Raf-1 disruptor peptide for 4 h leads to an increase of activating ERK1/2 
phosphorylation that could be mediated by a large number of effectors acting through 
ERK during T cell activation (134). 
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3.4 Discussion 
Previous work has shown that PDE8A is expressed in activated CD4+ T cells (23, 24, 
32, 135). Functionally, we have reported that PDE8 regulates T cell motility as inhibition 
of PDE8 is a non-redundant means to suppress lymphocyte chemotaxis and adhesion 
(24, 32, 126). Moreover, we have recently shown that PDE8A is expressed in breast 
cancer cell lines and inhibition of PDE8 suppresses breast cancer cell migration (33). 
These previously described roles of PDE8 in cell motility prompted us to mechanistically 
investigate the specific cell migration categories and molecular signaling complexes that 
are regulated by PDE8. 
 
PDEs control intracellular cAMP gradients and are positioned in discrete signaling 
complexes. Much is known about spatial arrangements and specific functions of some 
PDE isoforms such as PDE4 (19, 20, 136). Much of this knowledge has stemmed from 
the use of disruptor peptides that have no effect on global PDE activity but can 
discretely displace small pools of tethered PDE from precise microdomains. For 
example, PDE4D5 forms signaling complexes with signaling and adhesion molecules 
that regulate spreading of cancer cells (45) and endothelial inflammation (137). A dearth 
of information, however, exists for complexes involving PDE8A. A recent study Baillie 
and colleagues demonstrated the first such PDE8 specific signaling complex (46). In 
this study, we addressed a major gap in the literature by delineating the parts of the 
mechanism by which PDE8 inhibition acts in T cells, and by investigating the function of 
the PDE8A-Raf-1 complex in T cells. To analyze T cell migration under physiological 
conditions, we did motility assays under shear flow conditions. To delineate the role of 
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PDE8 in different T cell populations involved in pro- and anti-inflammatory immune 
responses, we subjected polyclonal and antigen-activated Teff and Treg cells to 
physiological shear stress in flow chamber assays. Our results indicate the higher 
adhesion and TEM potential of naive Treg cells compared to naive Teff cells. Further 
activation of these cells with plate bound anti-CD3 led to an increase in migratory 
potential of Teff cells compared to the Treg cells. Our results indicate that enzymatic 
inhibition of PDE8 using the specific PDE8 inhibitor, PF-04957325, leads to significant 
reduction of Teff cell adhesion. In contrast, Treg motility is not profoundly affected by 
PDE8 inhibition. This differential effect on both the cell populations is consistent with the 
observed differential expression of PDE8A in Teff cells versus Treg cells where it is 
considerably more highly expressed in Teff cells. Treatment with the PDE8A-Raf-1 
disruptor peptide had a more potent effect on Teff cell adhesion, which suggested the 
specific involvement of the PDE8A-Raf-1 signaling complex in the control of CD4+ T cell 
motility beyond a role for the global pool of PDE8 in T cells. In order to dissect the 
molecular mechanism by which PDE8 and the PDE8A-Raf-1 complex regulate 
adhesion, we further tested the effect of the enzymatic inhibitor and signaling complex 
disruptor on interaction of activated CD4+ T cells isolated from lymph nodes of mice 
immunized with MOG35-55/CFA with endothelial ligands, VCAM-1 and ICAM-1, 
molecules critically involved in inflammation (131). Treatment with the disruptor peptide 
led to a significant reduction in firm adhesion, spreading and locomotion of Teff cells as 
well as reduction in firm adhesion of Treg cells while interacting with ICAM-1. Thus 
PDE8A-Raf-1 signaling complex regulates LFA-1 integrin mediated tether formation 
while interacting with ICAM-1 vascular adhesion molecules. LFA-1 ICAM-1 interaction is 
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also necessary in the immune synapse, hence PDE8-Raf-1 kinase complex can also be 
important in CD4+ T cells and antigen presenting  cells interaction. The expression of 
αL, α4 integrin and CD44 expression in CD4+Foxp3-GFP- Teff cells and 
CD4+Foxp3+GFP+ Treg cells after treatment with PDE8 enzymatic inhibitor was 
marginally reduced or unaltered suggesting that the effect on adhesion was dependent 
on cell adhesion molecules activation rather than cell surface expression (Fig. S3A, B) 
(138, 139). Importantly, neither PF-04957325 nor disruptor peptide treatment affected 
the viability of the cells (Fig. S4).  
 
It is noteworthy that our data suggest a Raf-1 dependent but ERK independent effect of 
PDE8 inhibition on T cell motility. Previous reports implicate Raf-1 and B-Raf in 
regulating migration by controlling Rho GTPase mediated downstream signaling which 
regulates actin cytoskeletal and focal adhesion dynamics (140, 141). Our findings 
further confirm the role of Raf-1 in regulating this process and point towards existence 
of the novel signaling complex regulating CD4+ T cell motility. Raf-1 is the major 
downstream effector linking TCR mediated Ras activation to MEK1/2 and ERK1/2 (134). 
However, B-Raf has been identified as the most efficient in interacting with Ras (142, 
143) and in activating ERK (144-146). Importantly, ERK activation and cell proliferation 
can proceed independently of Raf-1, while Raf-1 can regulate the Rho downstream 
signaling during cell migration independently of ERK signaling (141), highlighting the 
independent regulation and function of these MAPKs in different signaling pathways. 
Importantly, in T cells, TCR stimulation can also lead to Ras/Raf-1-independent 
activation of ERK (134). Moreover, findings that PDE8 inhibition has little effect on T cell 
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proliferation (24, 126) indicates an ERK independent action. In contrast, PDE4 inhibition 
profoundly inhibits cell proliferation and ERK1/2 signaling (147), but has little effect on T 
cell motility (21, 126). Taken together, our findings that inhibition of PDE8 and the 
PDE8A-Raf-1 signaling complex leads to suppression of T cell motility in the absence of 
marked inhibition of proliferation indicates a novel role for a pool of PDE8A regulating 
Raf-1 kinase independently of downstream ERK1/2 signaling.  
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3.5 Materials and Methods 
Animals 
Female 6-8 weeks old C57BL/6 mice were obtained from Jackson laboratories, Bar 
Harbor, ME. Foxp3gfp.KI knock-in (Foxp3gfp.KI) mice were obtained as a gift from Dr. 
Kuchroo (148). Experiments were performed according to approved protocols at UConn 
Health (IACUC Protocol number 100794-1216). 
 
Chemicals and antibodies 
Recombinant mouse VCAM-1/CD106 Fc chimera, recombinant mouse ICAM-1/CD54 
Fc chimera were purchased from R&D systems, Minneapolis, MN. The primary 
antibodies for phospho-p44/42 MAPK (Thr202/Tyr204) (9101; 1:1000), p44/42 MAPK 
(9102; 1:1000), Phospho-Raf-1 (pSer259) (9421; 1:1000) and Raf-1 (9422; 1:1000) 
were purchased from Cell Signaling Technology. Anti-GAPDH (ab75834; 1:100,000) 
and anti-PDE8A antibodies (1:1000) were purchased from Abcam and Scottish 
Biomedical, respectively. The anti-CD3 antibody was purchased from Biolegend. The 
secondary antibodies goat anti-rabbit IgG HRP conjugated (1:4000) and chicken anti-
rabbit HRP (1:5000) were purchased from Invitrogen and Santa Cruz Biotechnology, 
respectively. The PDE8A-Raf-1 disruptor peptide (R454–T465; RRLSGNEYVLST) and 
scrambled control peptide (SYTVRLLGERNS) were synthesized as described (46). The 
PDE8 selective inhibitor PF-04957325 was synthesized by Pfizer Inc., Groton, CT (24). 
 
Isolation of Teff cells, Treg cells and CD4+ T cells 
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CD4+CD25- Teff and CD4+CD25+ Treg cells were isolated from the spleens of C57BL/6 
mice using the CD4+CD25+ Treg Isolation kit (Miltenyi Biotec) as published previously 
(135). Foxp3-GFP- Teff cells and Foxp3+GFP+ Treg cells were sorted based on GFP 
expression from CD4+ T cells isolated from the spleens of Foxp3gfp.KI mice. For the 
generation of activated pathogenic CD4+ T cells, C56BL/6 or Foxp3gfp.KI mice were 
immunized with MOG35-55/CFA 200 µg s.c. in the footpads (10, 11). On d 10 post-
immunization, CD4+ T cells were isolated from the draining popliteal lymph nodes (PLN) 
using the CD4+ T cell Isolation Kit (Miltenyi Biotec).  
 
Cell culture and treatments 
Murine brain endothelium derived cell line bEnd.3 (ATCC, Manassas, VA) was cultured 
in DMEM supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2mM L-
glutamine and 10% fetal bovine serum as described (24). In the flow assays, endothelial 
cells and CD4+ T cells were treated with 1 µM PF-04957325 PDE8 inhibitor or DMSO 
vehicle control for 45 min or 1 h, or with PDE8-Raf-1 disruptor peptide or control peptide 
10 µM for 4 h. For the flow assay with naive Teff cells or Treg cells, cells were cultured 
with plate-bound anti-CD3 (10 µg/ml) with or without IL-2 (NIH) (100 Units/ml) for 18 h. 
For integrin expression analysis, splenic CD4+ T cells isolated from Foxp3gfp.KI mice 
were cultured with plate-bound anti-CD3 (10 µg/ml) for 18 h followed by treatment with 
PF-04957325 or vehicle control for 1 h or disruptor or control peptide for 4 h. The cells 
were then pre-incubated with anti-CD16/32 (clone: 2.4 G2, BD Biosciences) for blocking 
Fcγ III/II receptors followed by surface staining with anti-CD4 eFluor 450 (clone: RM4-5, 
eBioscience), anti-CD11a BV510 (clone: M17/4, BD Horizon), anti-CD49d PerCp-
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eFluor710 (Clone: R1-2, eBioscience), anti-CD44 PE (clone:IM7, BD Pharmingen) 
antibodies. Events were acquired on LSR II (BD Biosciences). Flow cytometry data 
were processed on FlowJo software (Tree Star). For the Western blot experiments, 
CD4+ T cells were treated with the PF-04957325 or the disruptor peptide and respective 
vehicle or scrambled peptide controls for 1, 2 or 4 h followed by plate-bound 15 min 
activation with 5 µg/ml plate-bound anti-CD3.  
 
Shear stress (flow) assay 
The bEnd.3 cells were stimulated with 1.25 µg/ml LPS for 18 h on d 4 after seeding. The 
parallel plate flow chamber (Glycotech) was assembled onto the endothelial cell plate 
and mounted onto the stage of an inverted phase contrast microscope (Nikon Eclipse 
Ti) (139). The CD4+ T cells were treated as described above and then were washed 
with cation free HBSS and resuspended in binding buffer [HBSS with CaCl2 and MgCl2, 
10 mM HEPES (Life Technologies) and 2 mg/ml BSA fraction V (Roche)] at a 
concentration of 106 cells/50 µl binding buffer. The CD4+ T cells were then infused over 
the endothelial cell layer at a constant low shear rate using a programmable syringe 
pump (Harvard Apparatus). Once the cells accumulate on the bEnd.3 cells, the shear 
rate was increased to 5 dyn/cm2 for the entire 15 min of the assay (migration phase) 
and a time-lapse video recording was done under phase contrast and GFP illumination 
settings using Nikon NIS imaging software. The cells and the binding buffer (entire 
system) were maintained at 37 °C throughout the assay. Motion analysis was done 
manually on all the T cells that are present in the microscopic field of view.  Each T cell 
was individually tracked starting from the accumulation phase throughout the migration 
 	 	 	 	 	65	
phase. Only the T cells that were present during the accumulation phase were 
analyzed. The distinct cell tethers that were examined are defined as follow: cells that 
detach immediately after application of shear flow were considered to be detached; cells 
that roll on the endothelial cell surface were rolling; cells that firmly adhere to the 
endothelial cell surface and remain stationary for at least 1 min were defined as 
adhesion; cells that form non-stationary adhesion, spread and migrate along the 
endothelial cell surface were included in the adhesion and locomotion category, cells 
that undergo TEM were included in the adhesion and TEM category. The number of 
cells in each category were counted and expressed as percentage of initially 
accumulated cells during the accumulation phase. For flow assays with immobilized 
vascular ligands, recombinant VCAM-1 Fc (2 µg/ml) or ICAM-1 Fc (5 µg/ml) (in 20 mg 
/ml BSA in PBS) was overlaid on protein A pre-coated polystyrene plates overnight at 4 
°C. Plates were then washed with PBS three times followed by blocking with 20 mg/ml 
BSA solution for 2 h at 37 °C. The immobilized vascular ligands coated plates were 
assembled as lower wall of the flow chamber as mentioned above. The interactions of 
the CD4+ T cells with the adhesive substrates were manually tracked as mentioned 
above. The cell tether examined were rolling, transient tether, firm tether, spreading, 
locomotion and detachment (138). Transient tether was defined as cells that stay for 
less than 4 s after flow starts, firm tether was defined as cells that stay for more than 4 s 
after flow starts, rolling was defined as cells that persistently rolled for at least 2 s after 
the flow starts, adherent cells were defined as cells that stay throughout the 15 min 
shear flow period. Spreading cells were defined as cells that increase their area, 
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perimeter and also undergo darkening of the edges (149). Cells undergoing spreading 
and migration were included in the locomotion category. 
 
Western blot 
CD4+ T cells were centrifuged at 2000 rpm for 5 min, washed twice with ice-cold PBS 
and lysed using RIPA buffer (Teknova) supplemented with protease inhibitor cocktail 
(1:100) (Sigma-Aldrich) and phosphatase inhibitor cocktail (1:10) (Roche). The lysates 
were then centrifuged at 10,000 rpm for 10 min to remove the cells debris. Protein 
concentration was determined using BCA Protein Assay kit (Pierce). Equal amounts of 
protein were loaded and run on 10% SDS-PAGE gel. Proteins were then transferred 
onto a nitrocellulose membrane (Bio-Rad Laboratories). The membrane was blocked for 
1 h at room temperature with 5% non-fat dry milk in Tris- buffered saline (Bio-Rad) 
supplemented with 0.1% tween-20 (Sigma-Aldrich) (TBS-T) before adding the primary 
antibodies in 5% BSA in TBS-T and incubated overnight at 4 °C. Membranes were 
washed three times with TBS-T, followed by incubation with horseradish-peroxidase-
conjugated secondary antibody (HRP) in 5% non-fat dry milk in TBS-T at room 
temperature for 2 h and washed 3 more times. Proteins were visualized and quantitated 
with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) using Syngene 
G:Box with GeneSnap BioImaging software. Probing with ERK1/2 and Raf-1 antibody 
was used for loading control for phospho ERK1/2 and phospho Raf-1 respectively.  
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Statistical analysis 
Experimental groups were compared by analyzing data with Student’s unpaired t-test 
using GraphPad Prism version 7.00 for Mac. Probability levels for statistically significant 
differences are indicated by the p value in the results and corresponding asterisks in the 
figures. (*P<0.05, **p<0.002, ***p<0.0002, **** p<0.0001).   
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Figure 3.1 
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Figure 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 	 	 	 	70	
Figure 3.1 
 
 
Fig. 3.1: Differential motility of naive and in vitro activated CD4+ Teff and Treg 
cells while interacting with endothelial cell monolayers under shear stress 
conditions. 
(A) Adhesion of CD4+CD25- Teff cells and CD4+CD25+ Treg cells isolated from spleens 
assayed under shear stress conditions (5 dyn/cm2); naive (for naive Teff and naive Treg 
cell flow assays: n=4, 2 independent experiments), anti-CD3 stimulation (for anti-CD3 
activated Teff cell assays: n=5, 3 independent experiments; anti-CD3 activated Treg cell 
assays: n=7, 6 independent experiments) and anti-CD3 + IL-2 (anti-CD3 + IL-2 Teff cell 
assays: n=7, 3 independent experiments; anti-CD3 + IL-2 Treg cell assays: n=5, 3 
independent experiments ). (B) Percentage of Foxp3-GFP- Teff cells and Foxp3+GFP+ 
Treg cells within the CD4+ T cell population isolated from spleens of Foxp3gfp.KI mice 
before and after sorting by flow cytometry.  (C) TEM and (D) detachment of anti-CD3 
activated CD4+Foxp3-GFP- Teff cells and CD4+Foxp3+GFP+ Treg cells sorted based on 
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GFP expression from Foxp3gfp.KI mice under shear stress (flow). (Foxp3-GFP- Teff cell 
assays: n=4, 2 independent experiments; Foxp3+/GFP+ Treg cell assays: n=3, 3 
independent experiments.) Data (mean ± SEM) are expressed as percentage out of 
total cells present in the flow chamber before the start of flow. 
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Figure 3.2 
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Figure 3.2 
 
Fig. 3.2: PDE8 inhibition at the catalytic moiety suppresses CD4+ Teff cell 
motility but not Treg cell motility. 
(A) The immunoblot shows PDE8A and Raf-1 expression of in vivo MOG35-55 
activated CD4+CD25- Teff and CD4+CD25+ Treg cells isolated from the draining 
PLNs. (B) Relative PDE8A expression normalized to GAPDH. Data are from T 
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cells isolated from lymph nodes of 5 mice. (C, D) LPS activated endothelial cells 
and MOG35-55 primed CD4+ T cells were treated with either vehicle or 1 µM PF-
04957325 for 1 h. Adhesion and detachment of CD4+Foxp3-GFP- Teff cells (C) 
and CD4+Foxp3+GFP+ Treg cells (D) were analyzed under shear stress. Data 
represent mean ± SEM results from 4 independent experiments and are 
expressed as percentage of total cells that accumulate in the flow chamber 
before the flow starts. Percentage of cells in each category is normalized to the 
vehicle condition set at 100 percent. 
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Figure 3.3 
 
 
 
Fig. 3.3: Disruption of the PDE8A-Raf-1 complex suppresses both CD4+ Teff 
and Treg cell motility. 
LPS activated endothelial cells and MOG35-55 primed CD4+ T cells were treated 
with either 10 µM scrambled (control) peptide or disruptor peptide for 4 h. 
Adhesion and detachment of CD4+Foxp3-GFP- Teff cells (A) and 
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CD4+Foxp3+GFP+ Treg cells (B) were analyzed under shear stress. Data 
represent mean ± SEM results from 3-4 independent experiments and are 
expressed as percentage of total cells that accumulate in the flow chamber 
before the flow starts. Percentage of cells in each category is normalized to the 
vehicle condition set at 100 percent. 
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Figure 3.4 
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Figure 3.4 
 
 
 
Fig. 3.4: Adhesiveness to ICAM-1 significantly affected by disruption of the 
PDE8A-Raf-1 complex, but not by PDE8 inhibition at the catalytic moiety. 
MOG35-55 primed CD4+ T cells were treated with vehicle or 1 µM PDE8 inhibitor 
for 1 h (A) or 10 µM control peptide or disruptor peptide for 4 h (B, C). 
Spontaneous tethering (adherent cells, spreading or locomotion) of the 
CD4+Foxp3-GFP- Teff cells (A, B) and CD4+Foxp3+GFP+ Treg cells (C) while 
interacting with high density ICAM-1-Fc (5 µg/ml) were analyzed under flow. Data 
represent mean ± SEM results from 3 independent experiments and are 
expressed as percentage of total cells that accumulate in the flow chamber 
before the flow starts. Percentage of cells in each category is normalized to the 
vehicle condition set at 100 percent. 
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Figure 3.5 
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Figure 3.5 
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Figure 3.5 
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Fig. 3.5: Inhibition of PDE8 in CD4+ T cells diminishes ERK1/2 
phosphorylation induced by CD3. 
MOG35-55 primed CD4+ T cells were treated with vehicle or 1 µM PF-04957325 for 
1 h followed by anti-CD3 stimulation for 15 min. Cell lysates were then probed for 
(A, B) phospho Raf-1 (S259), Raf-1, phospho ERK1/2, ERK1/2, (C) PDE8A and 
GAPDH by Western blot. (B, C) Bands were quantitated by densitometry and 
data are presented as phospho-Raf-1 (S259) relative to Raf-1, phospho-ERK1/2 
relative to ERK1/2 and PDE8A expression relative to GAPDH. Data represent 
mean ± SEM results from 4 independent experiments (n=7). 
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Figure 3.6 
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Figure 3.6 
 
 
Fig. 6: Disruption of the PDE8A-Raf-1 complex in CD4+ T cells increases 
inhibitory Raf-1 phosphorylation at serine 259 and increases ERK1/2 
phosphorylation induced by CD3. 
MOG35-55 primed CD4+ T cells were treated with 10 µM control peptide (CP) or 
disruptor peptide (DP) for 4 h (A) followed by anti-CD3 stimulation for 15 min. 
Cell lysates were then probed for phospho Raf-1 (S259), Raf-1, phospho ERK1/2 
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and ERK1/2 by Western blot. (B) Bands were quantitated by densitometry and 
data are presented as phospho-Raf-1 (S259) relative to Raf-1 and phospho-
ERK1/2 relative to ERK1/2 at 4 h. Data represent mean ± SEM from 2 
independent experiments (n=5). 
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Figure 3.S1 
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Figure 3.S1 
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Figure 3.S1 
	
 
Fig. 3.S1: Adhesiveness to ICAM-1 significantly affected by disruption of 
the PDE8A-Raf-1 complex, but not by PDE8 inhibition at the catalytic 
moiety. 
MOG35-55 primed CD4+ T cells were treated with vehicle or 1 µM PDE8 inhibitor 
for 1 h (A, B) or 10 µM control peptide or disruptor peptide for 4 h (C, D). 
Spontaneous tethering (rolling, transient tether, firm tether, spreading, 
locomotion) and detachment of the CD4+Foxp3-GFP- Teff cells (A, C) and 
CD4+Foxp3+GFP+ Treg cells (B, D) while interacting with high density ICAM-1-Fc 
(5 µg/ml) were analyzed under flow. Data represent mean ± SEM results from 3 
independent experiments and are expressed as percentage of total cells that 
accumulate in the flow chamber before the flow starts. Percentage of cells in 
each category is normalized to the vehicle condition set at 100 percent. 
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Figure 3.S2 
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Figure 3.S2 
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Fig. 3.S2: Firm adhesiveness of CD4+ T cells to VCAM-1 is not affected by 
PDE8 inhibition at the catalytic moiety or by disruption of the PDE8A-Raf-1 
complex. 
MOG35-55 primed CD4+ T cells were treated with either vehicle or 1 µM PF-
04957325 for 45 min (A) or 10 µM control peptide or disruptor peptide for 4 h (B). 
Spontaneous tethering (rolling, transient tether, firm tether, adherent cells) and 
detachment of the CD4+ T cells while interacting with high density VCAM-1- Fc (2 
µg/ml) were analyzed under shear stress of 5 dyn/cm2. Data represent mean ± 
SEM results from 4 independent experiments and are expressed as percentage 
of total cells that accumulate in the flow chamber before the flow starts. 
Percentage of cells in each category is normalized to the vehicle condition set at 
100 percent. 
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Figure S3 
	
Fig. S3: Integrin surface expression is not altered by PDE8 inhibition at the 
catalytic moiety and marginally reduced by disruption of the PDE8A-Raf-1 
complex.  
CD4+ T cells isolated from spleens of Foxp3gfp.KI mice were treated with plate-
bound anti-CD3 (10 µg/ml) for 18 h followed by treatment with vehicle or 1 µM 
PF-04957325 for 1 h or 10 µM control peptide or PDE8A-Raf-1 disruptor peptide 
for 4 h. Expression of αL integrin, α4 integrin, and CD44 was evaluated by flow 
cytometry. Data show MFI of the αL+, α4+ and CD44+ cells within the Foxp3-GFP- 
Teff cell (A) and Foxp3+GFP+ Treg cell populations (B). Data represent mean ± 
SEM results from 1 experiment (n=3). 
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
10000
20000
30000
40000
αL
 in
te
gr
in
 M
FI *
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
500
1000
1500
2000
2500
α4
 in
te
gr
in
 M
FI
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
1000
2000
3000
4000
C
D
44
 M
FI
*
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
5000
10000
15000
20000
αL
 in
te
gr
in
 M
FI
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
1000
2000
3000
4000
α4
 in
te
gr
in
 M
FI
Ve
hic
le 
co
ntr
ol
PF
-04
95
73
25
Co
ntr
ol 
pe
pti
de
Di
sru
pto
r p
ep
tid
e
0
1000
2000
3000
4000
5000
C
D
44
 M
FI
A
B
 	 	 	 	 	93	
Figure S4 
	
	
	Fig. S4: Inhibition of PDE8 or disruption of the PDE8A-Raf-1 complex does not 
affect viability of CD4+ T cells.  
The viability of the CD4+ T cells after treatment was assessed using the trypan blue 
assay. The graphs represent the percentage of live and dead cells within each 
treatment group. Data represent mean ± SEM results from 1 experiment (n=3).		
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Chapter 4 
Targeting Phosphodiesterase-8 (PDE8) suppresses accumulation of immune cells 
to the central nervous system in experimental autoimmune encephalomyelitis 
 
4.1 Summary 
Phosphodiesterases have been used as targets for treatment of inflammatory, diseases 
with two PDE4 inhibitors recently approved for treatment of psoriasis/psoriatic arthritis 
and COPD. We have previously demonstrated PDE8 and PDE8A-Raf-1 kinase complex 
mediated regulation of MOG35-55 activated CD4+ effector T cell adhesion and locomotion 
under shear flow conditions. In this paper, we have explored treatment with PDE8 
specific inhibitor in a T cells mediated disease model-experimental autoimmune 
encephalomyelitis (EAE). We report a suppression of clinical signs of disease after 
treatment with PDE8 inhibitor PF-04957325 in chronic and relapsing-remitting EAE. 
Further, there is reduction in infiltrates in the CNS as observed by histology and 
counting mononuclear cells isolated from spinal cord. Additionally, the PDE8 inhibitor 
treatment induces a relative increase in anti-inflammatory phenotype by increasing the 
percentage of IL-10 producing CD4+ T cells and reducing encephalitogenic Th1, Th17 
cells in the CNS. Our study demonstrates the importance of targeting PDE8 in 
autoimmune inflammation model without affecting the immunoregulatory Treg cells. 
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4.2 Introduction 
cAMP is a known regulator of physiological functions in a cell and is a known target for 
regulating immune responses and inflammation (77). Extracellular ligand binding to G 
protein coupled receptors (GPCRs) lead to cAMP synthesis via activation of adenylyl 
cyclase and convertion of ATP to cAMP. Activation of T cells lead to a transient 
upregulation of cAMP levels, which is then degraded by phosphodiesterase enzymes 
(150). PDE are the only known enzymes that are able to hydrolyse and hence maintain 
spatial and temporal control over formation of cAMP gradients within a cell (19, 20). 
PDEs are divided into 11 different gene families based on their specificity for cAMP or 
cGMP, structural similarity and mode of regulation (21). Specific PDE forms induced in 
activated lymphocytes are PDE1, PDE3, PDE4, PDE7 and PDE8 (16, 22-25). Out of 
these PDE3, PDE4B and to a lesser extent PDE7A are the major forms of PDE 
expressed in activated T cells (26). PDE4 inhibitor - rolipram has been used to 
ameliorate clinical signs of EAE models and reduce CNS inflammation when treatment 
is started after immunization or after onset of disease (27, 28). PDE3 inhibitors alone 
are ineffective at treating Th1 mediated disorders. But PDE4 inhibitor and low doses of 
PDE3 inhibitors - cilostamide in combination synergistically inhibit T cell proliferation 
and pro-inflammatory cytokine production of human cells (26). PDE7 inhibitor have 
proved ineffective in suppressing T cell proliferation and mice deficient in PDE7A have 
functional T cells (29, 30). But PDE7 inhibitors when used in combination with PDE4 
inhibitors show an additive effect (31). These reports suggest that probably there might 
other PDEs expressed in T cells that might be important for controlling T cell function. 
Our previous work has shown that PDE8 is important for chemotaxis of T cells and 
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adhesion of T cells to endothelial cells (24, 32). PDE8 has a very high affinity for cAMP 
with a km value in the range of 40-150 nM (40 fold higher than that of PDE4) and hence 
might function at lower cAMP concentrations than PDE4 (34). PDE8A is insensitive to 
inhibition by non-specific PDE inhibitor IBMX but is inhibited by the PDE inhibitor 
dipyridimole (DP) (IC50 in the range of 4- 9 µM) (21). Work from our lab has shown that 
only treatment with dipyridamole inhibits chemotaxis of concanavalin A activated 
splenocytes (32). Whereas, inhibition of PDE3, PDE4 or PDE7 did not affect 
chemoattractant induced migration of cells. Since dipyridamole also inhibits PDE8, this 
was the first evidence that PDE8 might be an important regulator of migration. Broad 
PDE inhibitor Dipyridamole treatment at high doses (100 mg/kg-300 mg/kg) on day 7 or 
day 20 post EAE induction leads to reduction in disease severity and reduction in 
microglial reactivity (151).  
 
PDE8A is expressed in activated CD4+ T cells and we have proven that it regulates 
adhesion of MOG35-55 activated CD4+ effector T cells to inflamed brain endothelium. 
PDE8A forms a complex with Raf-1 kinase and protects it from cAMP effector protein 
PKA mediated phosphorylation. We have previously shown that disruption of PDE8A-
Raf-1 kinase complex also inhibits MOG35-55 activated CD4+ effector T cells to inflamed 
brain endothelium under shear flow conditions (Basole et al., under review). PDE4 
inhibitors increased adhesion of CD4 T cells, and when added along with PDE8 inhibitor 
reduced the suppression of adhesion. This indicates that PDE8 and PDE4 regulate 
different pools of cAMP in CD4+ T cells and hence regulate different cAMP mediated 
functions.  Our previous studies have demonstrated that PDE8 does not effect T cells 
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proliferation, ex vivo cytokine production but specifically targets motility of CD4+ T cells. 
We have also shown that PDE8 is expressed at higher levels in acute inflammatory 
stage compared to the tolerant stage in lung draining hilar lymph nodes in a Ovalbumin 
induced allergic airway disease model (126). This evidence points towards the need for 
targeting PDE8 in inflammatory diseases. Further, our findings that PDE8 is expressed 
at higher levels in naive and MOG35-55 activated effector T cells (Teff cells) compared to 
regulatory T cells (Treg cells) and PDE8 inhibition specifically affects Teff cell adhesion 
and not Treg cell adhesion, indicates that this can be a beneficial treatment for 
specifically targeting pathogenic Teff cells. Our current study explores targeting PDE8 in 
vivo in EAE using a highly specific PDE8 inhibitor (IC50 for PDE8A = 0.0007 µM, PDE8B 
< 0.0003 µM, other PDE isoforms >1.5 µM) which was first reported in our publication 
(21).  
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4.3 Results 
Therapeutic effect of treatment with the PF-04957325 in active EAE and adoptive 
transfer EAE   
To examine whether PDE8 mediated regulation of CD4+ T cell motility has implications 
in vivo, we tested effect of PF-04957325 on a T cell mediated disease. Active EAE was 
induced in C57BL/6 mice using MOG35-55/CFA. Mice with a grade 1 or grade 2 clinical 
disease were then treated with PF-04957325 or vehicle control s.c thrice daily for 10 
days from day 13 to day 22. We observed a clinical suppression of disease in the PF-
04957325 treated group compared to mice in the vehicle treated group (Fig. 4.1A, 
***p=0.0007). However, mice in the PF-04957325 group again increased in disease 
severity once the treatment was stopped. After testing the inhibitor in chronic disease 
model, we next tested the effect of treatment with PF-04957325 in a relapsing-remitting 
disease model. Disease was induced in SJL mice by injecting them with PLP139-151 
activated lymph node cells. Mice were treated during the second relapse of disease 
from day 41 to day 50. Mice treated with PF-0495732 had reduced the severity of 
disease compared to mice treated with vehicle control (Fig. 4.1B, ***p=0.0004). For 
continuous drug delivery, we implanted osmotic pumps filled with PF-04957325 or 
vehicle control into the subcutaneous cavities of active or RR-EAE mice with grade 1 or 
2 disease. These pumps are designed to release the drug once they are in the body 
cavity at a flow rate of 0.5 µl/h for 14 days. In the active EAE model, PF-04957352 
treated mice had amelioration of clinical disease during the treatment period (day 12 to 
day 26) compared to the vehicle treated mice (Fig. 4.1C, ****p<0.0001). After the 14 d 
treatment period, the osmotic pumps were removed and the clinical scores of the mice 
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were monitored daily. As observed earlier once the treatment was halted, mice in the 
PF-04957325 treated group had clinical disease similar to mice in vehicle treated group. 
In the RR-EAE model, mice were implanted with the pumps on day 21 after the first 
relapse. Mice in the PF-04957352 treated group had a suppression of clinical disease 
compared to vehicle control treated mice (Fig 4.1D, ****p<0.0001). Although the 
treatment did not prevent occurrence of the third relapse, but the there was reduction in 
disease severity of the relapse. 
 
Treatment with the PF-04957325 suppresses infiltrates in the spinal cord and 
brain  
To test whether inhibition of PDE8 in vivo reduced accumulation of cells in the CNS, we 
treated grade 1 or 2 EAE mice with vehicle control/PF-04957325 for 4 d. Hematoxylin 
and eosin (H&E) staining of the brain and spinal cord sections on day 4 post treatment 
were performed in order to obtain a quantitative assessment of the infiltrates in the CNS 
(Fig 4.2A-B). There was significant reduction in infiltrates in the brain meninges (* 
p=0.0339), spinal cord parenchyma (* p=0.0245) and additive meningeal and 
parenchymal infiltrates (** p=0.0052) after treatment with PF-04957325 (Fig. 4.2C). We 
also counted the SC MNCs isolated from EAE mice treated with PF inhibitor for either 4 
days or 6-13 days using the trypan blue assay. There was a non-significant decrease in 
total number of MNCs accumulated in the spinal cord after 4 d treatment (0.701 × 106 
vs. 0.549 × 106; p=0.5203). 6-13 d treatment leads to a reduction in total number of 
MNCs accumulated in the SC (0.663 × 106 vs. 0.222 × 106; p=0.0783) (Fig. 4.3A), 
however this reduction was not significant. At the 4 d treatment timepoint, there was an 
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increase in sequestration of cells in the cervical (1.663 × 106 vs. 4.2 × 106; **p=0.0035), 
inguinal lymph nodes (5.053 × 106 vs. 9.533 × 106; p=0.1128) as well as in the spleen 
(76.043 × 106 vs. 131 × 106; p=0.3223) (Fig. 4.3B-D). We observed a slight non-
significant decrease in the cells in the cervical (1.636 × 106 vs. 1.251 × 106; p=0.4397) 
and inguinal lymph nodes (1.331 × 106 vs. 0.947 × 106; p=0.4631), whereas a slight 
non-significant increase in the total number of cells in the spleen (66.366 × 106 vs. 
72.985 × 106; p=0.7416) after 6-13 d treatment. Thus short treatment leads to 
sequestration of cells in the peripheral lymphoid organs and slight decrease in cell 
infiltrates in the spinal cord. 6-13 d treatment further decreases cell infiltrates in the 
spinal cord while equalizing the cell number in the periphery. 
 
Treatment with the PF-04957325 suppresses CD4 effector T cell accumulation in 
the spinal cord but does not affect Treg cells accumulation 
In order to effect if CD4+ T cells accumulation into the spinal cord was being affected by 
the treatment, we did a detailed FACS analysis on the MNCs isolated from the spinal 
cord of EAE mice after 4 d and 6-13 d treatment (Fig. 4.4A).  
PDE8 inhibition in vivo does not change the percent and total number of CD4+ T cells, 
CD4+/Foxp3- Teff cell accumulating in the spinal cord after 4 d treatment (Fig. 4.4B-C). 
On the contrary, after 6-13 d treatment we observed a decrease of the total number of 
CD4+ T cells (1.21 × 105 vs. 2.13 × 104, p=0.0597) and CD4+/Foxp3- Teff cells (1.02 × 
105 vs. 1.72 × 105, p=0.0535), although the decrease was not statistically significant. 
There wasn’t a significant effect on percent and total number of CD4+/Foxp3+ Treg cells 
infiltrating in the spinal cord (Fig. 4.4D). The selective effect of the PDE8 inhibition on 
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Teff cells and not Treg cells is consistent with our previous observations that PDE8 
inhibition affects MOG35-55 activated Teff cell adhesion and not Treg cell adhesion in 
vitro under shear flow conditions (Basole CP et al., under review). To assess whether 
PDE8 inhibition in vivo was affecting the proliferation of cells in the spinal cord, we 
analyzed percent and total number of Ki-67+ cells within the Teff and Treg cell 
populations. 4 d treatment does not affect the percent and total number of Ki-67+ cells 
within the Teff cells (Fig. 4.4E) and Treg cells (Fig. 4.4F) populations.  But there is a 
significant decrease in total number of Ki-67+ Teff cells in the spinal cord after 6-13 d 
treatment (3.03 × 104 vs. 6.42 × 103, **p=0.0049). 
 
Treatment with the PF-04957325 suppresses pro-inflammatory cytokine 
production and induces IL-10 production in the spinal cord 
In order to assess the effect of PDE8 inhibition on inflammation in the spinal cord and 
periphery, we analyzed the pro-inflammatory and anti-inflammatory cytokine synthesis 
after PMA-ionomycin stimulation post 4 d and 6-13 d treatment with PF-04957325. 4 d 
treatment leads to significant reduction in percentage (82.5% to 70.43%; p=0.0248) and 
total number (0.78 × 105 vs. 0.26 × 105; *p=0.0297) of TNF-α+ producing CD4+ T cells in 
the spinal cord (Fig. 4.5A). There wasn’t any significant differences in the percentages 
and total number of IL-17, IFN-γ, IL-17+/IFN-γ+ production (Fig. 4.5B-D) in CD4+ T cells 
after 4 d treatment. 6-13 d treatment, there was a non-significant decrease in percent of 
IL-17 producing CD4+ T cells in the spinal cord. However there wasn’t any effect on 
IFN-γ, IL-17+/IFN-γ+ production in CD4+ T cells. In addition, 6-13 d treatment showed 
similar TNF-α synthesis in the CD4+ T cells and CD11b+ monocytes in the spinal cord. 
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Since we observed a clinical suppression of disease after long term treatment, we 
tested whether there were any changes in IL-10 production in CD4+ T cells (Fig. 4.6). 
There was 4.44% increase in percent (14.03% to 18.47%; p=0.3603) and significant 
decrease in total number (2.96 × 103 vs. 1.37 × 103, *p=0.0388) of IL-10 producing 
CD4+ T cells. There was only a 1.296% increase in IL-10 production in the CD11b+ 
monocytes (2.042% vs. 3.338%; p=0.2723) 
 
Relative increase in Treg cells in the spinal cord compared to pathogenic CD4+ T 
cells after treatment 
There is a significant increase in Foxp3+/Tregs cells compared to TNF- α producing 
CD4+ T cells in the spinal cord following PF-04957325 treatment as observed by the 
decrease in TNF-α to Treg ratio (4.6 vs. 1.99; *p=0.0174) (Fig. 4.7A). In addition, there 
was also a relative increase in Treg cells in the spinal cord compared to Th1 and Th17 
cells (Fig. 4.7B-D), although this increase was not statistically significant.  
 
Effect of PDE8 inhibition on peripheral immune response: There was a significant 
increase in total number of CD4+ T cells, Teff cells, Treg cells as well as B cells in the 
cervical lymph nodes after 4 d treatment with PF-04957325 compared to vehicle control 
treated mice (Fig. 4.8A-D). We also analyzed ex vivo cytokine production after 
PMA/Ionomycin stimulation and found that there was significant increase TNF- α 
producing CD4+ T cells (Fig. 4.8E). In the spleen, there was significant increase in the 
total number Teff cells after PDE8 inhibition compared to vehicle treated EAE mice (Fig 
4.8F). In the draining inguinal lymph nodes, there was also significant decrease in the 
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pathogenic Th17, TNF- α producing CD4+ T cells and TNF- α producing CD11b+ 
monocytes (Fig 4.9A-C). Thus PDE8 inhibition in vivo leads to sequestration of the 
pathogenic T cells in the periphery within the lymph nodes and spleen. We assessed IL-
10 production in the cervical lymph nodes and spleen after 6-13 d treatment. There 
wasn’t much difference in the percentage and total number of IL-10 producing CD4+ T 
cells and CD11b+ monocytes in the cervical lymph nodes and the spleen (Fig 4.10A-D).  
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4.4 Discussion  
Early studies on characterization of PDEs in human lymphocytes had shown them to be 
excellent targets for producing anti-inflammatory effects with PDE4 the predominant 
form expressed (52). But bringing PDE4 inhibitors into the clinics faced decades of 
challenges, mostly due to emetic side effects. However, the approval and clinical use of 
PDE inhibitors for the treatment of major human inflammatory disorders has now finally 
made tremendous progress over the last 6 years with indications expanding at an 
almost yearly pace (53-70, 152).  There is currently intense further interest and activity 
in the development of selective inhibitors of additional PDE gene families to target 
inflammation. Our study shows that inhibition of PDE8 in both chronic and RR EAE 
disease models suppresses clinical disease, although this effect lasts only long as the 
inhibitor is administered in vivo. This can be due to short half life of the inhibitor and 
reversible type of inhibitor. Effectiveness of inhibitors also depends on whether 
inhibitors act reversibly or irreversibly. Most inhibitors are reversible, hence they bind to 
the enzyme through non-covalent bonds and act on ATP binding site or catalytic site. In 
this case, the cells can recover their enzymatic activity quickly. With irreversible 
inhibitors, forming covalent with the enzyme and thus have increased biochemical 
efficiency of target disruption, reduced sensitivity toward pharmacokinetic parameters 
and increased duration of action that outlasts pharmacokinetics of the compound (153).  
 
We have tried to elucidate the mechanism by which PDE8 inhibits cell migration into the 
CNS by treating EAE mice for either 4 d or 6-13 d timepoint. 4 d treatment leads to 
accumulation of the pathogenic CD4+ T cells in the lymph nodes and spleen. The exact 
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mechanism of blocking lymphocyte egress from the lymph nodes after PDE8 inhibition 
is unknown. Long term treatment blocks CD4+ T cell infiltration into the spinal cord 
possibly by affecting integrin mediated adhesion of CD4+ T cells to the vascular 
endothelial cell of the blood brain barrier. Once these CD4+ T cells enter the spinal cord, 
their reactivation might also be blocked since. We have shown previously that disruption 
of PDE8-Raf-1 complex suppresses adhesion by affecting LFA-1 integrin mediated cell 
tethers with ICAM-1. Since LFA-ICAM-1 is crucial part of T cell activation at the 
immunological synapse, it is possible that in vivo CD4+ T interaction with antigen 
presenting cells is affected. This might explain the reduction in total number of Th17 
cells and proliferating CD4+ T cells observed in the spinal cord. The inhibitor has 
selective effect in the CNS as we did not see any effect on cytokine production in the 
periphery after 6-13 d treatment. MS patients who receive Natalizumab (Tysabri) 
treatment (a monoclonal antibody against α4 integrin subunit of α4β1 integrin) are at 
risk of progressive multifocal leukoencephalopathy (PML) due to impaired immune 
surveillance (154). Since PDE8 is not the major PDE expressed in CD4+ T cells, 
inhibition of PDE8 may not lead to profound effect on immune surveillance. Additionally, 
due to the short on and off rates and their oral availability, PDE inhibitors can be dosed 
very efficiently and quickly removed from the circulation should side effects emerge. 
 
Selective effect of PDE8 inhibition on Teff cells infiltration in the spinal cord and not 
Treg cell infiltration will be beneficial treatment option in autoimmune diseases. Previous 
reports indicate that treatment with PDE4 inhibitor significantly improves Treg cell 
mediated suppression of Th2 response in allergic airway disease (155).  PDE4 inhibitor 
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Rolipram at therapeutically relevant doses leads to side effects such as emesis and also 
did not reduce the lesions in the brain of MS patients (37). PDE inhibitors are now 
emerging to be important targets for treating inflammatory diseases, with PDE4 inhibitor 
Apremilast (Otezla) now being approved for treatment of psoriasis and psoriatic arthritis. 
Combined treatment with PDE8 and lower doses of PDE4 inhibitor might be better 
treatment option since it improves patient compliance and might increase the Treg cell 
infiltrates in the CNS as well as increase their suppressive capacity. The recent paper 
from Hoffman and colleagues have discovered a dual PDE4/8 inhibitor BC8-15 (IC50 for 
PDE8A and PDE4 is 0.28 µM and 0.22 µM respectively) (97). Effect of this inhibitor on 
clinical suppression of disease and leukocyte infiltration of T cells in the CNS in the EAE 
model needs to be tested in the future. 
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4.5 Materials and Methods 
Animals 
Female 4-6 weeks old C57BL/6 and SJL mice were obtained from Jackson laboratories 
(Bar Harbor, ME) and were used for the autoimmunity studies. Experiments were 
performed according to approved protocols at UConn Health (IACUC Protocol number 
100794). 
 
Peptides for EAE induction: MOG35−55 peptide corresponding to mouse sequence 
(MEVGWYRSPFSRVVHLYRNGK) was purified by the Yale University Synthesis 
Facility and Hebrew University. PLP139-151  corresponding to sequence 
(HSLGKWLGHPDKF) was synthesized peptide synthesis facility at Hebrew University 
(156). 
 
Induction of Active EAE: Four to six week old mice were immunized with MOG35−55 
in Complete Freund’s Adjuvant (CFA; Sigma-Aldrich) as previously described by us 
(99). A total of 200 µg of MOG35−55 peptide and 400 µg of killed Mycobacterium 
tuberculosis (Difco Laboratories) was emulsified in CFA and injected s.c. into the flanks 
of mice. The mice were also injected with 200 ng Pertussis toxin (Biological 
Laboratories Inc.) i.p on day 0 and day 2 post- immunization.  
 
Induction of Adoptively transferred EAE: Female donor SJL mice were immunized 
with 200 µg PLP139-151 and 400 µg of killed Mycobacterium tuberculosis emulsified in 
CFA and s.c injected into the flanks. Day 10 post immunization, the draining inguinal 
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lymph nodes were harvested and made into a single cell suspension. Cells were 
washed in RPMI media with 1% L-glutamine, 1% penicillin/Streptomycin and HEPES. 
LNCs were stimulated with 10 µg /ml PLP139-151 at a concentration 2 million cells/ml in 
tissue culture media (RPMI media with 1 % L-glutamine, 1 % penicillin/Streptomycin, 
HEPES, 10 % heat inactivated serum and 1 % 5 x 10-3 M 2–mercaptoethanol) for 4 d. 
LNCs are detached from the well, counted and washed with PBS. Each recipient mouse 
is injected with 22-30 million cells in 200 µl PBS i.p. 
 
Clinical Evaluation of EAE: Mice will be scored daily according to a non-linear grading 
scale from 1-5 as follows: 0, no disease; 1, tail weakness; 2,hind limb paresis/marked 
slowing of righting; 3, complete paralysis of hindlimbs; 4, severe forelimb 
weakness/paralysis; 5, moribund or dead (99, 157). The cumulative disease index (CDI) 
will be obtained by summing the daily average disease scores of each experimental 
group from the first day after beginning of treatment. A mean of these daily disease 
scores (MDD) will be calculated over the entire treatment period based on the number 
of treatment days. (158) 
 
Treatment: The PDE8 selective inhibitor PF-04957325 was synthesized by Pfizer Inc., 
Groton, CT (24). Mice with a grade 1 of grade 2 disease were treated with PF-04957325 
(2 mg/ml) 10 mg/kg/dose or vehicle control s.c injections twice daily for 4-13 days for 
short term histology or FACS experiments. For long term treatment experiments were 
either injected s.c thrice daily for 10 d (10 mg/kg/dose) or were implanted s.c with mini-
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osmotic pumps filled with PF-04957325 (22 mg/ml) (15.5 mg/kg/day) or vehicle control 
for 14 d. Mice were scored and weighed daily during and after the treatment was over. 
 
Histology of brain and spinal cord: Mice were sacrificed by intra-cardiac perfusion 
with 20 ml cold PBS under isoflurane narcosis. Brain and spinal cord were extracted 
and fixed by immersion in 10% phosphate buffered formalin, paraffin embedded and 
sectioned (6-7 µM). Three longitudinal sections spanning the entire length of the spinal 
cord, three cross-sections at different levels in the spinal cord, and four to five sections 
of brain and brain stem were stained with hematoxylin and eosin (H&E) for each animal 
(99). Total number of inflammatory foci (over 10 mononuclear cells) per visual field in 
the brain and spinal cord were quantified in meninges & parenchyma by an expert 
double blinded and not aware of the treatment group of the mice (99, 159). 
 
Flow cytometry staining: Mice were sacrificed by intra-cardiac perfusion with 20 ml 
cold PBS under isoflurane narcosis. Spinal cord is enzymatically digested by incubation 
with Collagenase D (Roche Diagnostics) and DNase I (Sigma) at 37°C for 45 minutes. 
Mononuclear cells are isolated by passing through a cell strainer followed by percol 
gradient (70%/37%) centrifugation (148, 160). Total number of mononuclear cells 
isolated from the spinal cord is determined by trypan blue exclusion method. Teff cells 
and Treg cells characterization: Mononuclear cells are first stained with cell surface 
molecules CD3, CD4, CD8, CD49d/α4 integrin and CD11a/αL integrin from E-
Bioscience. Intracellular staining is done with transcription factor Foxp3 from E-
Bioscience (160). Percentage of cells, absolute number of cell and MFI are determined 
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while analyzing FACS data. In addition we will do a similar analysis of the T cell 
populations in the regional cervical lymph nodes, spleen and inguinal lymph nodes. 
Cytokine staining: Mononuclear cells are first treated with phorbol 12-myristate 13-
acetate (PMA) (Sigma), Ionomycin (Sigma) and brefeldin A (Sigma) in order to induce 
synthesis of cytokines for 4 hours at 37°C. The cells are then permeabilized and fixed 
with the BD bioscience buffers followed by intracellular staining with TNF-α 
(eBioscience), IL-17 (BD Biosciences) and IFN-γ (Biolegend) antibodies (160, 161). For 
IL-10 staining: After PMA/Ionomycin/BFA stimulation,the cells will be stained for surface 
markers and fixed with 4% PFA. Next day, cells are permeabilized using BD 
permeablization buffer followed by intracellular staining with IL-10 (clone: JES5). 
 
Statistical Analysis: Treatment effects were assessed by comparing the mean daily 
disease scores of both experimental groups using the nonparametric Wilcoxon 2 
sample analysis/ Mann-Whitney U test using GraphPad Prism. For comparison of total 
number of cells, proliferation, cytokine analysis unpaired t test was used.  
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Figure 4.1 
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Figure 4.1 
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Figure 4.1. Treatment with the PDE8 enzymatic inhibitor ameliorates disease in 
EAE mice. (A) C57BL/6 mice with chronic EAE treated with PF-04957325 10 
mg/kg/dose or vehicle control s.c 3 times from day 13 to day 22. Data represents mean 
scores  (mean ± SEM) per day for 6 mice per group. (B) SJL mice with relapsing 
remitting EAE were treated with 10 mg/kg/dose or vehicle control s.c 3 times each day 
from day 41 to day 50. Data represents mean (mean ± SEM) of 4-5 mice in each group. 
(C) C57BL/6 EAE mice were implanted with mini-osmotic pumps filled with either PF-
04957325 (15.5 mg/kg/day) in vehicle or vehicle (50 % DMSO and 50 % PBS) on day 
12 post-immunization. The pumps are designed to deliver the drug for 14 d. The pumps 
were removed at day 28 post-immunization. Data represent the mean scores 
(mean+SEM) per day for 4 mice in each treatment group. p<0.0001 between d12-d26 
treatment days, p<0.0001 between d27-d46, p<0.0.01 between d47-d58 post-treatment. 
(D) SJL mice were implanted with mini-osmotic pumps filled with either PF-04957325 
(15.5 mg/kg/day) in vehicle or vehicle (50% DMSO and 50% PBS) on day 21. The 
pumps are designed to deliver the drug for 14 d. The pumps were removed at day 38 
post- immunization. Data represent the mean scores (mean+SEM) per day for 3 mice in 
each treatment group. p<0.0001 between d21-d35 treatment days, p<0.05 between 
d36-d49, p<0.0001 between d50-d60 post-treatment. P value was calculated using 
Mann-Whitney non-parametric test. 
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Figure 4.2 
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Figure 4.2. Treatment with PF-04957325 suppresses infiltration of cells into the 
brain and spinal cord. EAE mice were treated with vehicle control or PF-04957325 
from day 10 to day 13 (4 d) followed by isolation of brain and spinal cord for histology. 
H/E images of the brain (A) and spinal cord (B) sections of vehicle control (grade 4) and 
PF-04957325 (grade 2) treated mice at 10X. (C) Graph represents the inflammatory foci 
present in the spinal cord parenchyma (p) and brain meninges (m) based on H/E 
sections. (n=5) 
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Figure 4.3 
 
Figure 4.3. Treatment with PF-04957325 suppresses infiltration of cells into the 
spinal cord. EAE mice with grade 1-3 disease were treated with PF-04957325 or 
vehicle control either twice daily for 4 d or thrice daily for 6-13 d. Data represents the 
total number of cells in the spinal cord (A), spleen (B), cervical lymph nodes (C) and 
draining inguinal lymph nodes (D) counted by trypan blue assay (n=3-7). 
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Figure 4.4. 
A 
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Figure 4.4 
 
Figure 4.4. Treatment with PF-04957325 suppresses CD4+ T cells and Teff cells 
accumulation into the spinal cord. (A) Detection of Foxp3+ Treg cells, Foxp3- Teff 
cells and Ki-67+ Teff and Treg cells by flow cytometry in spinal cord mononuclear cells 
of EAE mice treated with vehicle control or PF-04957325.Data represents percent and 
total number of CD4+ T cells (B), Foxp3-/Teff cells (C), Foxp3+/Treg cells (D), Foxp3-/Ki-
67+ Teff cells (E), Foxp3+/Ki-67+ Treg cells (F) analyzed by flow cytometry. (n=3-5) 
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Figure 4.5 
A 
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Figure 4.5 
 
Figure 4.5. Treatment with PF-04957325 decreases the Th1 and Th17 cells in the 
spinal cord. (A) Detection of TNF-α+, IL-17+ and IFN-γ+ CD4+ cells after ex vivo 
restimulation with PMA/Ionomycin by flow cytometry in spinal cord mononuclear cells of 
EAE mice treated with vehicle control or PF-04957325. Representative dot plots show 
CD4+ T cells that are positive for TNF-α+ (above), IL-17 (x-axis) and IFN-γ+ (y-axis). 
Data represents percent and total number of TNF-α+ (B), IL-17+ (C) and IFN-γ+ (D) and 
IL-17+ IFN-γ+ (E) CD4+ cells. 
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Figure 4.6 
A 
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Figure 4.6. Treatment with PF-04957325 increases the IL-10 producing CD4+ T 
cells in the spinal cord. (A) Detection of IL-10+ CD4+ cells after ex vivo restimulation 
with PMA/Ionomycin by flow cytometry in spinal cord mononuclear cells of EAE mice 
treated with vehicle control or PF-04957325. Data represents percent and total number 
of IL-10+ CD4+ T cells (B) and IL-10+ CD11b+ cells (C). 
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Figure 4.7 
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Figure 4.7. Relative decrease in pathogenic CD4+ T cells and increase in Treg 
cells in the spinal cord after treatment with PF-04957325 
The above graphs show the ratio of percent (left graphs) or total number (right graphs) 
TNF-α+ (A), IL-17+ (B) and IFN-γ+ (C) and IL-17+ IFN-γ+ (D) CD4+ cells to Treg cells in 
the spinal cord mononuclear cells of EAE mice treated with vehicle control or PF-
04957325. 
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Figure 4.8 
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Figure 4.8 
 
 
Figure 4.8. 4d treatment with PF-04957325 leads to accumulation of cells in the 
peripheral lymphoid organs 
Data represents percent and total number of CD4+ T cells (A), Foxp3-/Teff cells (B), 
Foxp3+/Treg cells (C), B cells (D), TNF-α+ CD4+ T cells (E) in the cervical lymph nodes 
and Foxp3-/Teff cells in the spleen (F) of EAE mice treated with vehicle control or PF-
04957325 for 4 d or 6-13 d analyzed by flow cytometry. 
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Figure 4.9 
 
Figure 4.9. 4d treatment with PF-04957325 leads to accumulation of cells in the 
inguinal lymph nodes 
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Data represents percent and total number of TNF-α+ (A), IL-17+ CD4+ T cells (B) and   
TNF-α+ CD11b+ cells in the draining inguinal lymph nodes of EAE mice treated with 
vehicle control or PF-04957325 for 4 d analyzed by flow cytometry. 
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Figure 4.10 
 
 	 	 	 	 	130	
Figure 4.10. Treatment with PF-04957325 does not affect IL-10 producing CD4+ T 
cells in the peripheral lymphoid organs. Data represents percent and total number of 
IL-10+ CD4+ T cells  and IL-10+ CD11b+  monocytes in the cervical lymph node (A-B) and 
spleen (C-D) of EAE mice treated with vehicle control or PF-04957325 for 6-13 d and 
analyzed by flow cytometry. 
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Chapter 5 
Final Discussion 
 
cAMP signaling has been shown to be inhibitory to T cells activation, proliferation and 
cytokine production (77). Hence cAMP production via either using cAMP activators or 
inhibiting cAMP degradation through phosphodiesterase (PDE) inhibitors is a promising 
therapeutic approach for treatment of inflammatory diseases. Our research focuses on 
PDE8 gene family which is upregulated in T cells after anti-CD3/ anti-CD28 activation in 
vitro, as well as after in vivo activation with peptide. We have shown expression of 
PDE8 in CD4+ T cells population in different disease models - lung draining hilar lymph 
nodes in ovalbumin induced allergic airway disease model (AAD) over the course of the 
acute inflammatory disease and to recede at the late tolerant non-inflammatory stage, in 
vivo myelin oligodendrocyte protein activated cells, breast cancer cell lines, human 
breast cancer patient tissue as well multiple sclerosis PBMCS (33, 126). 
Overexpression of PDE8 in these various inflammatory conditions necessitated 
exploring importance of PDE8 in maintaining homeostasis. 
 
To evaluate PDE8A as a potential drug target, the selective and combined effects of the 
highly potent PDE8-selective inhibitor PF-04957325 was compared with the PDE4-
selective inhibitor piclamilast (PICL). As previously shown, PF-04957325 suppressed T 
cell adhesion to endothelial cells. In contrast, PICL alone increased firm T cell adhesion 
to endothelial cells by ~20% and significantly abrogated the inhibitory effect of PF-
04957325 on T cell adhesion by over 50% when cells were co-exposed to PICL and PF-
04957325. Despite its robust effect on T cell adhesion, PF-04957325 was over two 
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orders of magnitude less efficient than PICL in suppressing polyclonal Teff cell 
proliferation, and showed no effect on cytokine gene expression in these cells. More 
importantly, PDE8 inhibition did not suppress proliferation and cytokine production of 
myelin-antigen reactive pro-inflammatory Teff cells in vivo and in vitro. Thus, targeting 
PDE8 through PF-04957325 selectively regulates Teff cell interactions with endothelial 
cells without marked immunosuppression of proliferation, while PDE4 inhibition has 
partially opposing effects. Collectively, these data identified PF-04957325 as a novel 
function-specific tool for the suppression of Teff cell adhesion and indicate that PDE4 
and PDE8 play unique and non-redundant roles in the control of Teff cell functions.  
 
We then analyzed the differential effect of PDE8 on Teff versus Treg cells adhesion and 
identified the role of a novel PDE8A-Raf-1 kinase signaling complex in these cell types. 
Inhibition of PDE8 using a highly specific PDE8 inhibitor PF-04957325 suppressed 
MOG activated CD4+ effector T cells (Teff) mediated adhesion to inflamed brain 
endothelial cells under shear flow conditions by ~37%. However, the inhibition of PDE8 
does not effect the motility of Treg cells, which are more motile even under naïve 
conditions compared to the Teff cells. This differential effect on both the cell populations 
is consistent with the observed differential expression of PDE8A in Teff cells versus 
Treg cells where it is considerably more highly expressed in Teff cells under naive and 
activated states (135). PDE8 acts partially via the inhibiting ERK-MAPK signaling 
pathway. Further we have explored the role of the PDE8A-Raf-1 kinase signaling 
complex in CD4+ T cells. Disruption of this complex leads to ~87% suppression of total 
CD4+ T cell adhesion, ~43% reduction in Teff cell adhesion and no significant effect of 
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Treg cell adhesion while interacting with activated brain endothelial cells. 
Mechanistically the PDE8A-Raf-1 kinase complex acts by suppressing the LFA-1 
integrin mediated adhesion, spreading and locomotion while interacting with the 
endothelial ligand ICAM-1. Further we have shown that PDE8A-Raf-1 kinase acts via 
Raf-1 signaling independent of downstream ERK-MAPK pathway. This study 
demonstrates for the first time that T cell motility under physiological shear stress 
conditions is profoundly modulated by a pool of PDE8A. This effect is mediated by the 
interaction between PDE8A and Raf-1 kinase and constitutes a novel signaling axis for 
the investigation of T cell adhesion and migration. 
 
To study targeting PDE8 in a T cell mediated disease, we tested efficacy of the treating 
with PDE8 inhibitor therapeutically, in a mice model of multiple sclerosis (MS) known as 
experimental autoimmune encephalomyelitis (EAE). Treatment of mice with active EAE 
or mice with adoptive transferred EAE with PDE8 inhibitor after disease onset leads to 
suppression of clinical symptoms of the disease compared to the vehicle control treated 
mice. This effect of the inhibitor lasts as long as the inhibitor is administered in vivo. 
PDE8 inhibition has an effect of immune cell infiltration into the sites of inflammation –
brain and spinal cord. Specifically we found that there was a reduction in number of 
CD4+ Teff cells accumulating in the spinal cord. These findings confirm our hypothesis 
that PDE8 plays a role in regulating migration of CD4+ T cells. Further we observed 
there is a trend for increase in percent of Treg cells entering the CNS after PDE8 
inhibition. This observation is similar to our finding that PDE8 does not suppress Treg 
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cell adhesion to brain endothelial cells in vitro. PDE8 inhibition in vivo leads to reduction 
in CD4+ T cells with a pro-inflammatory phenotype (Th1 and Th17 cells). 
These findings suggest that targeting PDE8 can be a beneficial treatment option in 
autoimmune diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 	 	 	 	135	
Figure 5.1 
 
 
Figure 5.1: PDE8 and PDE8A-Raf-1 kinase complex regulate CD4+ T cell motility 
cAMP signaling leads to inhibitory phosphorylation of Raf-1 at serine 259 which then 
cannot activate downstream ERK-MAPK signaling. PDE8 has been recently shown to 
associate with Raf-1 kinase protein and create a compartment of low cAMP and protect 
Raf-1 from PKA medated inhibitory phosphorylation. The diagram describes the two 
approaches used to study CD4 T cells motility - Targeting PDE8 enzymatic activity with 
PF-04957325 and PDE8-Raf-1 kinase signaling complex using disruptor peptide. 
PDE8A-Raf-1 kinase regulates adhesion via the affecting the LFA-1-ICAM-1 interaction. 
PDE8 regulates adhesion in Teff cells via unknown mechanisms. 
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Chapter 6 
Future directions 
 
6.1 Role of PDE8 and PDE8A-Raf-1 kinase complex in regulating endothelial cells 
adhesion molecule expression and barrier functions 
We have previously started to study the effect of the PDE8 inhibition on brain 
endothelial cells bEnd.3 cells using PDE inhibitor dypyridamole, which inhibits PDE8 
with an IC50 in the range of 4-9 µM (24).  PDE8A gene expression in endothelial was 
four fold lower than expression of PDE4B, which was the most abundant PDE gene 
expressed in bEnd.3 cells. There was significant reduction in expression of vascular 
recruitment molecules important in mediating interaction of T cells - VCAM-1 and ICAM-
1, after treatment with dypyridamole. In addition there was a reduction in expression of 
claudin-5 tight junction protein important in regulating vascular permeability. 
 
We now want to explore the effect of PDE8 selective inhibitor PF-04957325 on protein 
expression of vascular adhesion molecule and tight junction proteins.  
PDE4 inhibitor Roflumilast suppressed the histamine- induced permeability rat 
mesenteric microvascular permeability in vivo and thrombin induced HUVEC (human 
vascular endothelial cells) permeability in vitro (162). The study also shows the 
inhibition of PDE4 inhibits LPS induced leukocyte endothelial interaction in vivo. Thus it 
would be interesting to test the effect of the dual PDE4/8 inhibitor on bEnd.3 cells. 
 
6.1.1 PDE8A protein expression in brain endothelial cells 
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Since we used mouse brain ECs – bEnd.3 cells in our in vitro flow chamber motility 
assays, we assessed the effect of PDE8 and PDE8A-Raf-1 kinase complex on ERK 
signaling. We first analyzed expression of PDE8A in bEnd.3 cells and found 2 PDE8A 
transcripts robustly expressed in bEnd.3 cells with or without LPS stimulation (Fig. 6.1). 
The molecular weights of the transcripts were approximately 93 kDa and 88 kDa 
suggesting that they represent PDE8A1 and PDE8A2 splice variants. 
 
6.1.2 Effect of PDE8 inhibition and disruption of the PDE8A-Raf-1 complex in 
brain endothelial cells   
Next, we stimulated bEnd.3 cells with LPS for 18 h followed by treatment with PF-
04957325 or disruptor peptide or RKIP inhibitor locostatin for 1 h western blot (Fig. 
6.2A). There was a slight increase in ERK1/2 phosphorylation after treatment with PF-
04957325. Treatment with disruptor peptide for 1 h did not show any effect on ERK1/2 
phosphorylation (Fig 6.2B). This is preliminary data presented from one experiment. 
More experiments need to be done to test the effect on Raf-1 and ERK signaling 
pathway. Also, we need to test the effect of PDE8 and PDE8A-Raf-1 kinase on vascular 
permeability by analyzing expression of vascular adhesion molecules (ICAM-1, VCAM-
1) and tight junction proteins (claudin-5) in endothelial cells by western blot and flow 
cytometry.  
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6.2 Exploring PDE8A expression in human samples 
Recent studies have identified PDE8 as an important drug target in autoimmune, 
neurodegenerative disorders and cancer. PDE8A1 transcripts have been shown to be 
altered and elevated in systemic lupus erythematosus (SLE) (163). PDE8A expression 
is elevated in breast cancer patient tissue and highly recurrent AKAP13-PDE8A fusion 
transcripts have been observed in colorectal cancer patient samples and cell lines 
(164). In addition, PDE8B expression is increased in alzheimer disease brains (165).  
In a collaborative blinded study using de-identified PBMC samples from MS patients at 
the Department of Neurology, Ohio State University (Lab of Dr. Lovett-Racke), we have 
analyzed PDE8A expression in PBMCs samples from MS patients (experiment 
performed by Dr. Hongli Dong). PDE8A is robustly expressed in these human PBMC 
samples (Fig. 6.3).  
In order to look at PDE8A expression in other immune cell populations, we have also 
analyzed PDE8A expression in de-identified human B cell samples from Department of 
Internal Medicine-Rheumatology at University of Michigan Medical School (Lab of Dr. 
Steven Lundy). PDE8A is expressed in the human B cell samples (Fig. 6.4).  Our goal is 
to test whether there is variation in PDE8 expression in patients with different forms of 
MS and in other autoimmune disorders. Further we want to test whether treating human 
CD4+ T cells as well other immune cells with PF-04957325 and dual PDE4/8 inhibitor 
has an effect on motility of cells. We need to obtain CD4+ T cells isolated from patients 
and healthy donors and treat them in vitro with the PDE8 enzymatic inhibitor and dual 
PDE4/8 inhibitor and test the effect on motility of the cells while interacting with 
HUVECs (human vascular endothelial cells) under shear flow conditions. 
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6.3 Combined treatment with PDE8 and PDE4 inhibitors 
 
A previous study from the Beavo lab has shown that PDE4 and PDE8 act in conjunction 
to regulate cAMP pools that control testosterone production (166). This is an interesting 
concept put forward by Beavo and colleagues who suggested that cAMP dependent 
processes in Leydig cells may be regulated by signaling microdomains that include 
PDE4 and 8. Therefore, dual inhibition of PDE4 and 8 might be a suitable means to 
treat pathologies caused by defects in steroidogenesis and this may also apply to pro-
inflammatory T cell functions (166, 167). 
Demirbas D et al. discovered a dual PDE4/8 inhibitor BC8-15 using yeast high 
throughput screening assay (97). BC8-15 inhibits PDE8A and PDE4A with an IC50 of 
0.28 µM and 0.22 µM respectively. They also identified two structural derivatives: 1] 
BC8-15A which has reduced potency against both PDE4 and PDE8 (IC50 1.59 µM for 
both PDE8A and PDE4A) and 2] BC8-15C has reduced potency against PDE8A (59.32 
µM) while retaining activity against PDE4A (IC50 0.13 µM). They further tested effect of 
BC8-15 treatment testosterone production in leydig cells. They found that treatment with 
the dual PDE4/8 inhibitor leads to a more elevation of testosterone release from leydig 
cells compared to treatment with rolipram alone. Thus we need to test the effect of the 
dual PDE4/8 inhibitor on motility of activated CD4+ T cells under flow. PF-04957325 
treatment in EAE has a small effect on clinical suppression of disease and immune cell 
infiltration into the CNS (Basole C et al., unpublished). Testing the dual PDE4/8 inhibitor 
might be a better treatment option since PDE4 inhibitors lead to amelioration of disease 
and suppression of inflammatory cytokines in the EAE model (28). 
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Figure 6.1 
 
Figure 6.1: PDE8A expression in un-stimulated and LPS stimulated bEnd.3 cells. 
bEnd.3 cells activated with LPS (1.25 µg/ml) for 18 h. Cell lysates were then probed 
with PDE8A and GAPDH by western blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 	 	 	 	141	
Figure 6.2 
 
 
Fig 6.2. Effect of the PDE8 inhibitor and disruptor peptide on LPS activated brain 
endothelial cells. 
(A) bEnd.3 cells activated with LPS (1.25 µg/ml) for 18 h followed by treatment with 
Vehicle control (VC)/ 1 µM PF-04957325 (PF) for 1 h or 10 µM control peptide (CP)/ 
disruptor peptide (DP) for 1 h. Cell lysates were then probed for phospho ERK1/2, 
ERK1/2 by Western blot. (B) Graph shows the level of phospho-ERK1/2 relative to 
ERK1/2. 
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Figure 6.3A 
 
Figure 6.3 PDE8A expression in human PBMCs samples from MS patients 
Cell lysates were probed with PDE8A and GAPDH by western blot. (Experiment 
performed by Dr. Hongli Dong.) 
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Figure 6.4 
 
Figure 6.4 PDE8A expression in human B cell samples 
Cell lysates were probed with PDE8A and GAPDH by western blot. (Experiment 
performed by Rebecca Nguyen.) 
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